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SUMMARY 
 
Background. The Spondyloarthritis (SpA) are a group of a multifactorial diseases 
characterised by a complex interplay between an inherited background and 
environmental factors that lead to immune response dysregulation and inflammation of 
the joints, mainly the sacro-ileal. Different from rheumatoid arthritis, there are no 
specific biomarkers for disease activity in the SpA that could be used in clinical 
practice. New biomarkers discovery could be helpful for early diagnosis, monitoring of 
disease activity, as well as for prognosis, outcome measures, and for assessing treatment 
efficacy. In SpA patients, macrophages infiltrating the inflamed joints, derive from 
circulating monocytes, express not only inflammatory cytokines, like TNF-α, IL-1β or 
TGF-β, but also enzymes causing tissue destruction and remodelling, like 
metalloproteinases. Metalloproteinases (MMPs), MMP3 in particular, have been 
reported to be highly expressed in synovial tissue and in peripheral blood of SpA 
patients. Recent studies have showed that MMP8 and MMP9, in particular, are 
produced by peripheral blood mononuclear cells (PBMCs) if they are stimulated by 
calprotectin (S100A8/S100A9 heterodimer). The SpA synovial tissue is characterized 
by an increased vascularization and an infiltrate composed of nucleated polymorphs, 
macrophages and lymphocytes. In these cells calcium signals are essential for various 
cellular functions, including proliferation, differentiation, apoptosis, and gene 
transcription. The aims of this work are to investigate whether the TNF-α, IL-1β, TGF-
β, S100A8, S100A9, MMP3, MMP8 and MMP9 mRNA expression levels and 
intracellular calcium ([Ca2+]i) fluxes variations in PBMCs might be associated with 
SpA. 
Methods. The study population comprised 64 patients with a diagnosis of SpA (39 
males and 25 females; mean age±standard deviation: 39.5±13.2 years) and 100 healthy 
controls (58 males and 42 females; mean age±standard deviation: 46.6±8.5). Among 
patients, 26 (40.6%) had diagnosis of Ankylosing Spondylitis (AS), (modified New 
York criteria) and 38 (59.3%) had a diagnosis of Psoriatic Arthritis (PsA) (CASPAR 
criteria). Blood samples were collected and complete blood count, CRP, ESR, uric acid, 
ALT and glucose were evaluated. Relative quantification (Real Time PCR) of TNF-α, 
IL-1β, TGF-β, S100A8, S100A9, MMP3, MMP8 and MMP9 mRNA were performed. 
Intracellular calcium ([Ca2+]i) fluxes were studied in patients and controls monocyte 
cells by a fluorescent microscope.  
 IV 
Results. The mRNA expression levels in PBMCs of TNF-α, IL-1β, TGF-β were similar 
in AS and PsA patients when compared to controls. The variations of TNF-α, TGF-β 
and IL-1β were correlated each other. TNF-α mRNA expression levels also show a 
significant correlation if patient’s relatives with SpA where found (t=-2.5386, p=0.013).  
MMP8 and MMP9 mRNA expression levels did not vary between controls and patients, 
nor they were related to disease clinical activity indices. S100A9 mRNA expression did 
not vary, the expression of S100A8 (F=3.29, p=0.039) was reduced in PsA patients. 
S100A8 and S100A9 expression levels were significantly correlated with circulating 
inflammatory cells and S100A8 was correlated with CRP and ESR. Monocytes from 
healthy controls had evident and frequent ([Ca2+]i) oscillations, while SpA patients 
monocytes did not. The percentage of cells exhibiting ([Ca2+]i) oscillations profile was 
significantly lower in AS with respect to controls (F=6.15, p=0.003). The percentage of 
monocytes with intracellular calcium oscillations and the studied molecules were not 
correlated with the type of therapy or of drug used. 
Conclusions. SpA associates with a reduced expression of the inflammatory S100A8 
calcium binding protein and with a decreased intracellular calcium fluxes in patients' 
cells compared to healthy subjects, suggesting that the presence of the disease affects 
the "on-off" mechanisms that regulate the concentration of intracellular calcium.  
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ACPA: Anti-citrullinated protein/peptide antibodies  
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CRP: C-reactive protein 
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CVD: cardiovascular disease 
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ERK: extracellular signal-regulated kinases 
ESR: erythrocyte sedimentation rate 
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1. INTRODUCTION 
1.1 Spondyloarthritis 
Spondyloarthritis (SpA) is a heterogeneous group of articular inflammatory disordes 
characterised by a broad spectrum of clinical manifestations, laboratory abnormalities, 
radiological features and genetic susceptibility in particular the association with the 
major histocompatibility complex class 1 antigen, HLA-B27. In 1974, Moll and 
colleagues established the concept of seronegative spondarthritides of inter-related 
disorders characterized by common clinical and imaging features different from other 
rheumatic diseases [1]. SpA, in particular, is a condition in wich both axial and 
peripheral joints could be affected; the inflammation of the axial skeleton involved 
sacroiliac joints and spine; the peripheral arthritis, commonly occur in a characteristic 
pattern, asymmetric, oligoarticular and preferentially in the lower extremities.  
In SpA are also present extra-articular features, such as cutaneous (psoriasis, pustular 
lesions, erythemanodosum, pyoderma gangrenosum), ocular (uveitis) and mucosal (oral, 
intestinal, genital ulcers) manifestations as well as the inflammatory bowel disease 
(IBD) [2-4].  
The absence of the rheumatoid factor and of anti-citrullinated protein/peptide antibodies 
(ACPA) in serum allowed to distinguish these disorders from rheumatoid arthritis and is 
referred to seronegative term.  
The group of disease consist of psoriatic arthritis (PsA) or axial spondyloarthritis (ax-
SpA), wich includes ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-
axSpA); the less common subgroups enteropatic SpA wich is associated with 
inflammatory bowel disease (Crohn’s disease and ulcerative colitis), reactive arthritis 
and undifferentiated SpA (uSpA) [5]. 
Recent data showed that SpA tends to be associated with the development of some 
comorbidity like cardiovascular diseases (CVD), diabetes mellitus, osteoporosis (OP) 
and depressive disorders [6].  
Signs and symptoms, in particular spinal symptoms, of SpA may be mistakenly 
attribuited to other causes of low back pain; this can lead to delays in diagnosis and 
treatment of the disease and related comorbidities. This delay results in a disease 
progression and disability that compromise work ability, work quality and health related 
quality of life (HRQoL) of these patients [7]. 
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1.1.1 Classification criteria  
Spa is carachterized by heterogeneous presenting features, diagnosis in fact depends on 
a combination of symptoms, physical examination, imaging, environmental factors and 
laboratory tests. In the Table 1 there is a list of the main features of the disease: each of 
these should be taken into account in making diagnosis [8]. 
 
Features of patients with SpA 
Inflammatory back pain 
Good response to NSAIDs 
Positive family history of SpA 
HLA-B27-positive 
Increased CRP concentration 
Enthesitis 
Peripheral arthritis 
Dactylitis 
Prior urogenital or gastrointestinal infection 
Inflammatory bowel disease (IBD) 
Psoriasis 
Acute anterior uveitis 
Sacroiliitis detected by imaging (radiography or MRI) 
 
SpA= Spondyloarthritis; NSAIDs = Non-steroidal anti-inflammatory; CRP: C-reactive protein;  
MRI= Magnetic Resonance Imaging 
 
Table 1. Clinical, biochemical and genetic features of SpA [9].  
 
The classification of SpA in the different subgroups of the SpA family can be difficult 
in particularly by the overlap of several symptoms making difficult an early diagnosis.  
For these reasons, in the past decades, the classification criteria of SpA has been 
reviewed many times. In 1984 the modified New York (NY) criteria were the most 
classification criteria used for AS diagnosis; these criteria provided high specificity 
although they lack sensitivity, especially in the early phases of disease [10]. The 
diagnostic performance of modified New York criteria was based on clinical symptoms 
and signs and on the presence of radiographic sacroilitis. The modified New York 
criteria are only useful in the valuation of advanced disease and are strict limited to 
axial features of the disease [9]. In the early 1990s has been developed Amor criteria 
[11] and European Spondyloarthropathy Study Group (ESSG) criteria [12] due to the 
limitations of the modiefied NY criteria and to be applicable to early-stage and mild 
SpA. 
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In comparison with the modified NY criteria Amor and ESSG criteria cover the whole 
spectrum of SpA (including patients with undifferentiated SpA) and include a wider 
range of manifestations of the disease (Figure 1).  
 
 
 
Figure 1. Venn diagram of features of the SpA criteria sets [9].  
 
Amor and colleagues proposed a set of classification criteria for the whole group of 
SpA, allowing a patient to be classified as having SpA whatever the presenting 
symptoms. The Amor criteria do not have mandatory features for the classification but 
provide the score of 12 features covering 4 domains: symptoms, radiographic and 
genetic features, response to treatment. ESSG classification criteria required the 
presence of inflammatory back pain (IBP) and synovitis as a entry conditions. These 
criteria recognized five major subtypes of SpA: ankylosing spondylitis (AS), psoriatic 
arthritis (PsA), reactive arthritis (ReA), spondyloarthritis related to inflammatory bowel 
disease (IBD-SpA) and uSpA.  
The Amor criteria perform better than ESSG for early SpA showing higher sensitivity 
(85%) and specificity (90%) thanks to the inclusion of positivity for HLA-B27 and 
ocular manifestation [11]. Both sets of criteria cover the whole spectrum of SpA and 
were useful over the years in classification of this disease however they cannot 
differentiate axial from pheripheral disease, important distintion for providing good 
treatment strategies. 
The Assessment of SpondyloArthritis international Society (ASAS) developed new 
criteria sets for axial SpA in 2009 [13] and for pheripheral SpA in 2011 [14] mainly do 
to the limitations of existing classification criteria.  
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The ASAS did a large cross-sectional study to propose new criteria on the basis of the 
two main clinical features identified in daily practice: axial symptoms and peripheral 
involvement [4].  
ASAS classification criteria for axial and pheripheral SpA are shown in Figure 2. 
 
 
 
Figure 2. ASAS classification criteria for axial and pheripheral SpA [9]. 
 
One important advance among the ASAS classification criteria is the inclusion of the 
MRI (Magnetic Resonance Imaging) allowed identifying the signs of axial 
inflammation in the early stages of the disease. The ASAS group, in fact, proposed the 
term “axial spondyloarthritis” (axSpA) for the first time to describe the full spectrum of 
axial disease and the “pheripheral spondyloarthritis” to describe the full spectrum of 
SpA diseases predominantly affecting the pheripheral skeleton [3]. The sensitivity and 
specificity of the entire set of criteria were 83% and 84% respectively [15]. 
The advantage of ASAS criteria has contributed to a better understanding of the 
spectrum of axial and pheripheral SpA, timely identification to avoid treatment options, 
unnecessary diagnostic testing and to acknowledge patient morbidity.  
 
1.1.2 Incidence and prevalence of Spondyloarthritis 
In the last years, data on the incidence and prevalence of SpA have become particularly 
important to improve the management of target therapies and consequently the health 
care costs. 
Before the introduction of the ASAS criteria the global prevalence values of SpA were 
reported to be 1% [16,17] but range substantially, from 0.01% in Japan [18] to 2.5% in 
Northern Artic natives [19,20]. The incidence broadly vary from 0.48 cases per 100.000 
person/year in Japan [18] to 62.5 per 100.000 person/year in Spain [21].  
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These differences are mainly due to the heterogeneity in the populations analysed, 
variation in the used criteria and the number of partecipants included in each study. 
Classification criteria are often developed for conducting clinical trials and are not 
always be available for epidemiological studies. 
In different population and ethnic groups the incidence and prevalence of SpA widely 
vary and at least can be explained by differences in the prevalence of HLA-B27. 
The overall prevalence of SpA using ASAS criteria has been evaluated in only one 
study in 2015. Costantino et al. in a large population-based cohort study (GAZEL 
cohort) consisting of 20625 French subjects (representative of French population) 
analysed the prevalence of SpA, in reference of HLA-B27, and founded that the 
estimated prevalence was 0.43%. 
In healthy controls HL-B27 positivity rate was 6.9% and in SpA patients was 75% with 
an increased risk of developing the disease compared with HLA-B27 negative subjects 
[22].  
Zlatkovic-Svenda and colleagues, estimated the prevalence of SpA in Serbian 
population; similar to that for rheumatoid arthritis (RA) the prevalence of SpA was 
0.32% [23].  
 
1.1.3 Measures of disease activity and outcome 
In SpA, several tools for assessing disease activity and outcome are widely used in daily 
clinical practice. The most notably are: the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) 
wich are self-administrated questionnaires. BASDAI consists of a questions related to 
the patients’ self-assessment (e.g. fatigue, pain, swelling, axial and pheripheral 
symptoms, enthesopathy and duration and intensity of morning stiffness). To assess 
spinal mobility is used the Bath Ankylosing Spondylitis Metrology Index (BASMI) and 
to assess radiographic damage is used the modified Stroke Ankylosing Spondylitis 
Spinal Score (mSASSS) [24,25]. mSASS criteria defined the progression of 
radiographic changes focusing on the development of erosions and syndesmophytes in 
the lumbar and cervical spine.  
Recently, to improve the BASDAI index, ASAS has developed the Ankylosing 
Spondilytis Disease Activity Score (ASDAS). This score is calculated on the basis of: 
the spinal pain, the duration of morning stiffness, the overall global assessment and 
peripheral arthritis plus laboratory assessment of either C-reactive protein (CRP) and 
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erythrocyte sedimentation rate (ESR) (www.asas-group.org/clinical-
instruments/asdas_calculator/asdas.html).  
Maastricht Ankylosing Sponylitis Enthesitis Score (MASES) [26] and Disease Activity 
Score-28 (DAS-28) [27] evaluate the peripheral joint commitment through the count of 
tender/swollen joints and the evaluation of dactylitis and enthesitis.  
The spinal pain can be evaluated with a 10-cm visual analogue scale (VAS) and visual 
analogue scale of global disease activity (VASg) [28,29].  
Other predictors include a history of smoking and elevated levels of inflammatory 
markers at the baseline [30].  
The outcome indexes are important to support the clinicians in the choice of the 
treatements; recent data have suggested that long-term therapy with TNF-α inhibitors 
may reduce the rate of development of new lesions especially with early initiation of 
treatment and longer duration of follow-up [31].  
 
1.1.4 Diagnosis of Spondyloarthritis  
SpA diagnosis requires of the combination of assessment of symptoms, physical 
examination, imaging and laboratory analyses. In rheumatology available diagnostic 
criteria sets are usually designed and are also used in clinical practice. Diagnostic 
criteria are applied to individual patients and should be sensitive to the identification of 
patients at the early stage of the disease. The purpose of the diagnostic criteria is to 
distinguish “definite” patients who fulfill the criteria set from “probable” or “possible” 
patients who present only some features of the disease [32]. Early diagnosis and 
therapeutic intervention are important to modified disease progression and avoid 
unnecessary diagnostic and therapeutic procedures [33]. In SpA diseases, the presenting 
symptoms need to be distinguishd from those associated with other rheumatic 
conditions, moreover the absence of specific diagnostic biomarkers make it difficult to 
differentiate patients among inflammatory arthropaties group.  
In SpA, the absence of rheumatoid factor in serum is a typical feature and distinguish 
these disorders from rheumatoid arthritis.  
Levels of acute phase reactant as CRP or ESR can be higher in AS patients (40-50%), 
so a normal CRP or ESR does not rule out this condition. Levels of both of these acute 
phase reactants are higher in patients with AS than in those with nr-ax SpA.  
The presence of HLA-B27 is a useful tool for SpA diagnosis and is an integral part of 
the ASAS criteria for ax-SpA. The prevalence of HLA-B27 vaires among different 
 7 
ethnic groups, in fact 85-95% of AS white patients has HLA-B27 but only the 6% of 
HLA-B27 carriers in the general population develop the disease [34]. SpA diagnosis is 
also supported by imaging techniques to confirm the suspected diagnosis, to define the 
extent of disease and to monitor potential changes. The use of MRI to assess sacroiliac 
changes (inflammatory lesions of sacroiliac joints with definite bone marrow oedema 
and osteitis) is one of the important advance. Plain radiographs can detect only 
structural changes such as joint erosion and subchondral bone sclerosis seen at the late 
stage of the disease [4].  
The development of early strategies to reduce the diagnostic delay of SpA remains to be 
investigated.  
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1.2 Treatment 
The treatment goals for SpA include reducing symptoms, improving and maintaining 
spinal flexibility and normal posture, reducing functional limitation and decreasing the 
complication associated with the disease. Spa therapy is usually based on different 
treatment strategies based on main clinical manifestations; non-pharmacological 
methods (active exercise program) are often combined to drug therapies.  
 
1.2.1 Non steroideal anti-inflammatory drugs  
Non steroideal anti-inflammatory drugs (NSAIDs) agents is the first line therapy in 
patients with AS and PsA due to their good efficacy in reducing back pain and stiffness 
(48-72h after intake) [35]. There is no clear difference in the effectiveness of the 
different NSAIDs 
In accordance with the severity of symptoms, continuous NSAID treatment is 
recommended for persistently active symptomatic disease. On-demand treatment is used 
when continuous treatment causes unacceptable side effects and is recommended for 
stable SpA patients [36].  
Moreover, there is some evidence about the inhibitory effects of NSAIDs on 
radiographic progression in patients with AS. In a recent randomised multicentre study, 
Sieper and colleague enrolled and randomized 167 patients with AS for treatment with 
continuous or on demand diclofenac for two years [37] and demonstrated the efficacy of 
NSAID in the reduction of new bone formation in on demand group.  
In 2016, ASAS-EULAR recommendations suggested the continuous use of NSAIDs if 
symptoms recur after stopping or reducing the dose therapy. The continuous use of 
NSAIDs is based on the symptoms of the patients instead of a possible protective effect 
on structural damage progression [6].  
Recent studies demonstrated that there is no difference in the efficacy of different 
NSAIDs in AS (Indometacin, celecoxib, diclofenac, ketoprofen), the choice of the drugs 
should be based on patients history, risk factors for side effects and comoribities [38].  
 
1.2.2 Disease modifyng anti rheumatic drugs  
Conventional Disease modifyng anti rheumatic drugs (DMARDs) (methotrexate, 
sulfasalazine, leflunomide) have been shown to be effective for pheripheral arthritis and 
other extra-articular features such as psoriasis, uveitis, and inflammatory bowel disease 
 9 
[39-41]. According to the EULAR recommendations, patients with peripheral PsA 
should be treated with conventional syntetic DMARDs, as methotrexate (MTX) as a 
first choice, when patients still have active disease despite NSAID therapy. 
EULAR/ASAS recommendations indicated that in AS patients with peripheral arthritis, 
sulfasalazine is the treatment option [6, 42]. It is well known that DMARDs are not 
useful for treating axial involvements, in fact biological drugs should be considered the 
best choice in patients with ax-SpA or in patients with PsA with persistently high 
disease activity [5].  
 
1.2.3Biological agents 
The use of TNF-α inhibitors is strongly recommended for SpA patients whose 
symptoms are not controlled by conventional therapy or for whom conventional therapy 
has unaccettable side effects [36].  
Currently, five TNF-α inhibitors (infliximab, etanercept, adalimumab, golimumab and 
certolizumab) have been approved for clinical used for treatment SpA disease in the EC, 
USA and most other part of the world. Treatment with TNF-α inhibitors leads to a good 
improvement in all articular manifestations, CRP levels, MRI-detectable inflammation 
in sacroiliac joint or spine in patients when conventional treatment failed [43]. TNF-α 
inhibitors leads to an immediate reduction of disease activity (BASDAI, ASAS), 
improvement in function and spinal mobility (BASFI), pain reduction, reduction of 
pheripheral arthritis and enthesistis [44]. Partial or full remission of symptoms could be 
found in approximately 60% of patients who have an adequate response to these agents. 
The predictor of good response include: young age, short disease duration, high baseline 
levels of inflammatory markers and low baseline levels of functional disability, but 
patients at any disease stage may benefit [36]. 
TNF-α inhibitors comprise two types of agents: monoclonal antibodies (mAb) 
(infliximab, adalimumab, golimumab and certolizumab) and soluble receptors 
(etanercept). All TNF-α inhibitors have the same target but not all of them are equally 
efficacious in disease treatment (Figure 3).  
Infliximab is a chimeric monoclonal IgG1 Ab composed by a human costant domain 
and murine variable regions. Golimumab and adalimumab are full human Abs that were 
produced by recombinant technology and certolizumab is a humanized Fab’ fragment 
coniugated to polyethylene glicole (PEG) to increase the serum half-life. Etanercept is a 
fusion protein of the extracellular domain of human TNFR2 receptor coupled to the Fc 
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region without CH1 domain of human IgG1, etanercept binds circulating soluble TNF-α 
and prevent TNF interaction with the cell surface receptors [45]. 
 
 
Figure 3. Structure (A) and mechanisms of action (B) of anti-TNF-α agents [45].  
 
The various TNF-α inhibitors seem to be equally potent for the treatment of axial, 
peripheral and extra-articular features; etanercept is less effective than antibodies in 
treating anterior uveitis and inflammatory bowel disease and is not preferred in patients 
with these associated conditions.  
Some studies demonstrated that the risk for tubercolosis and possibly herpes zoster 
might be lower with etanercept than with the monoclonal antibodies infliximab and 
adalimumab [46-48]. Before the initiaton of TNF-α inhibitors, patients should be tested 
for the presence of latent or active tubercolosis.  
Generally, TNF-α inhibitors were found to be well tolerated and to improve healthy 
related quality of life but a high number of patients do not respond well to treatment in 
term to clinical, biological and imaging features that predict good response; primary 
non- responders patients (13-40%) fail to respond to initial TNF-α inhibitors and up to 
50% of the patients lose responsiveness during therapy (secondary non responder) [49]. 
In case of failure of the first TNF-α inhibitor a second drug where used since many 
patients respond to different type of anti TNF-α tratments [50,51]. During the last year, 
new other biological targets have been studied, and in case of failure or toxicity of an 
TNF-α inhibitors, it is possible to choose other class of biological drugs.  
Secukinumab, a monoclonal antibody that targets and neutralises Interleukin-17A (IL-
17) showed good results in both PsA and AS patients. Interleukin-17A seems to have a 
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role in PsA pathogenesis; an increased number of IL-17 producing cells have been 
found in circulation, joints and psoriatic skin plaques [52]. 
Different studies have suggested the role of Interleukin-12 (IL-12) and Interleukin-23 
(IL-23) in the pathophysiology of PsA. Ustekinumab, is a monoclonal antibody that 
target and inhibits the activity of both cytokines. Ustekinumab may be a therapeutic 
options in patients that presented skin and articular involvement [53]. 
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1.3 Psoriatic Arthritis 
Psoriatic arthritis (PsA) is a chronic, immune-mediated, inflammatory arthropathy 
associated with psoriasis and with inflammation of the joints and entheses. Psoriatic 
disease is characterized by varied clinical features which include enthesitis, dactylitis, 
nail dystrophy, uveitis and osteitis, in addition to associated comorbidities such as 
obesity, metabolic syndrome and cardiovascular disease [54]. PsA arises in about 30% 
of psoriasis patients and in 0.25% of the population [55]. The key feature of psoriatic 
arthritis is the inflammation of synovial membrane characterised by increased 
vascularisation and immune cell infiltration [56-58]. The immune cells release 
proinflammatory mediators that activate fibroblast-like synoviocytes, which then invade 
cartilage and bone. Further, osteoclast cells mediate bone resorption inducing joint 
deformity [59]. 
Traditionally, PsA is classified into five subtypes including: asymmetric oligoarticular 
pattern (involvement of five or fewer joints); symmetric polyarticular pattern 
(metacrpophalangeal and proximal interphalangeal joints involvement); distal 
interphalangeal joint disease pattern; spondyloarthropathy whose presentation is similar 
to AS and arthritis mutilans which is the most rare and severe form [60]. The prevalence 
of these specific pattern is variable, the most frequent is oligoarticular pattern even if 
patients with long term disease develop polyarticular pattern. 
Specific features of PsA are dactylitis (inflammation of an entire digit) and enthesisits 
(inflammation of the connective tissue between tendon or ligament and bone). MRI 
studies suggest that enthesitis precedes clinical joint involvement although this notion 
remains controversial [61].  
The primary forces driving the complex pathopysiology of PsA are mainly genetic, 
environmental and immunologic factors. 
PsA is characterised by complex genotypes and have a strong genetic component. Based 
on twin and family studies in European populations the genetic contributions in PsA 
appear approximately 80-100% for heritability [62].  
Compared to the most of the rheumatic diseases, heredity plays a particular important 
role in this form of SpA.  
Initial genetic studies identified the HLA locus on chromosome 6p, in particular HLA-
Cw6 locus, the strong determinant of psoriasis and psoriatic arthritis; recent study 
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published in 2016 indicated that this locus is primarly associated with cutaneous 
psoriasis [63], and HLA genes might define subphenotypes of PsA.  
Results derived from cross-sectional cohrt analysis reported that HLA-B27:05:02 
haplotype was positively associated with enthesis, dactylitis and symmetric sacroilitis, 
while HLA-B*08:01:01-HLA-C*07:01:01 haplotypes were associated with joint fusion, 
asymmetrical sacroilitis and dactylitis [63].  
Several studies have reported an association with PsA and other gene in the HLA region 
as TNF-α and its promoter and in non-HLA region including IL-1, IL-23R and Tumor 
necrosis factor alpha-induced protein 3 TNFAIP3 gene [63]. Additionally, major 
histocompatibility complex class I chain-related A (MICA) alleles are also considered 
to be associated with PsA [64]. 
In genetically susceptible subjects, environmental factors, including infections, trauma, 
stress, obesity and smoking have been implicated in causing psoriatic arthritis. In 24.6 
% of patients, the presence of local trauma precedes the development of PsA [65].  
Furhermore, small data are available about the role of microbiota in this disease. There 
is substantial evidence about the role of the involvement of CD-8 positive T cells and 
the activation of the TNF-α and interleukin 23-Th17 pathways for immune-mediated 
inflammation in the pathogenesis of psoriatic arthritis.  
The diverse range of PsA clinical features prevents its early detection and subsequent 
therapeutic intervention. Due to similarities to other inflammatory arthritides, the need 
for a diagnosis during pre-symptomatic and early clinical stages of PsA is well 
established.  
PsA detections, is guided by the criteria outlined in the Classification Criteria for 
Psoriatic Arthritis (CASPAR) that include both clinical and radiological features [66]. 
To meet the CASPAR criteria the patients must have inflammatory articular disease 
(joint, spine or entheseal) and higher than/equal 3 points from the following categories: 
current psoriasis or personal or family history of psoriasis; psoriatic nail dystrophy on 
current examination; negative rheumatoid factor; dactylitis (current or on history as 
recorded by rheumatologist); radiographic evidence of iuxta-articular new bone 
formation. The sensitivity and the specificity of these criteria are 91.4% and 98.7% 
respectively. 
Despite the advance in molecular technologies, PsA lacks of validated biomarkers for 
diagnosis, prediction of therapeutic response or remission of the disease. As 
demonstrated in a multicentre study conducted in a large cohort of Italian PsA patients, 
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CRP and ESR, the most popular laboratory markers of inflammation, are elevated in 
only half of the patients [67]. Serum levels of CRP is used as a measure of disease 
activity in PsA but also in several other inflammatory disease.  
Hansson and colleagues, to search better prognostic markers of PsA, showed that serum 
S100 calcium binding protein S100A8/S100A9 (S-calprotectin) levels were 
significantly higher in PsA patients and were a better predictor for disease than CRP 
levels [68]. 
The investigation of PsA serum proteome showed that several pro-inflammatory 
mediators are upregulated, including cytokines and chemokines [69].  
Significantly higher levels of interleukin-6 (IL-6) were detected in PsA patents respect 
to patients with cutaneous psoriasis (PsC) [70]. IL-6 correlated with CRP and ESR 
among PsA patients with joint manifestations and their levels seems to be associated 
with the disease activity.  
Chandran and colleagues discovered more potential diagnostic biomarkers in the serum 
of PsA patients, they found increased levels of highly sensitive CRP (hs CRP), 
osteoprotegerin (OPG) and matrix metalloproteinase 3 (MMP-3) [71]. 
Predictive biomarkers are important for distinguishing patients responders and non 
responders to target therapy and to avoid unnecessary expenses and risk of adverse 
events. The recommendations for the management of PsA have been developed by 
several expert groups and focused the attention at the pharmacological treatments 
although an optimal management of patients with PsA should also include non 
pharmacological strategies with patients education and regular exercise. At the 
international levels, Group for Research and Assessment of Psoriasis and Psoriatic 
Arthritis (GRAPPA) and EULAR developed the recomandations in 2009 and in 2012 
respectively and updates of these recommendations are currently ongoing [72,42]. 
Both of these sets of recommendations propose non-steroideal anti-inflammatory drugs 
as first treatment for joint inflammation then, if necessary, introduction of DMARDs 
such as methotrexate, sulfasalzine and lefunomide, and finally, if inflammation persists 
introduction of TNF-α inhibitors [72,42]. 
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1.4 Ankylosing Spondylitis 
Ankylosing spondylitis (AS), a prototype of the spondyloarthritis family, is a chronic, 
progressive, inflammatory disease of the axial skeleton that mainly involves the axial 
spine and sacroiliac joints [73] and can manifest with various clinical signs and 
symptoms. The characteristic symptoms of AS are spinal stiffness and loss of spinal 
mobility which originate from spinal inflammation, structural damage or both. Extra-
articular manifestations of the disease of AS include acute uveitis, pheripheral arthritis, 
enthesitis, psoriasis, aortic root and gut inflammation [74]. AS is also associated with an 
increased risk of cardiovascular disease principally due to the presence of systemic 
inflammation. AS is typically diagnosed in people aged from 20 to 40 years, about 80% 
of patients develop first symptoms when they are younger than 30 years. Less than 5% 
of cases have an onset after 45 years. AS is more common among male patients than 
female patients and the ratio is 3:1. Due to the insidiously progressive nature of AS, 
delay between onset of symptoms and diagnosis is up to 8-10 years [75].  
Modified New York criteria are used for AS diagnosis, these criteria based their 
diagnostic performance on clinical symptoms and signs and on the presence of 
radiographic sacroilitis [10].  
Different studies have demonstrated that the delay in the definition of structural damage 
is mainly due to the late appearance of definite sacroilitis using conventional plain 
radiographs.  
ASAS classification criteria take into account MRI techniques, able to show the 
presence of active inflammation. ASAS criteria permitted the classification of patients 
in an early phase of the disease when structural damage is not yet present [15].  
The discovery of biomarkers has been growing interest to facilitate early diagnosis of 
AS and appropriate selection of patients for treatment. Laboratory indices, as CRP and 
ESR, are generally non specific tool in diagnosis AS. About 50 to 70% of patients with 
active AS have elevated levels of both indices but normal CRP and ESR, however, not 
exclude the disease.  
In AS patients, the assessment of genetic profile is mandatory for diagnosis, there is a 
strong and well-established association of HLA-B27 with AS, more than 90% of 
patients had this haplotype [8].  
HLA-B27 is recentely proposed as a part of diagnostic algorithm in the diagnostic 
process of AS.  
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Novel molecular pathways that improve the understanding about AS are been 
discovered. In 2007, a genetic study identified variants among non-HLA genes as a risk 
factor of AS. Multiple genes are involved in the development and activity of a recently 
identified population of T helper (Th) cells known Th17 that produced IL-17, in the IL-
23/IL-23R pathways, in the influence the activity of the pro-inflammatory transcription 
factor nuclear factor kappa-light-chain-ehancer of activated B cells (NF-κB) and in the 
production of other inflammatory mediators [76]. 
Furthermore, other gene are involved in AS pathogenesis including endoplasmic 
reticulum aminopeptidase 1 (ERAP 1) that palys central role in peptide trimming, a step 
required for the generation of HLA peptide [36]. 
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1.5 Pathogenesis of Spondyloarthritis: Genetic factors 
SpA is a multifactorial disease and the pathogenesis are not yet fully understood. 
Genetic factors (HLA-B27 and non HLA-B27 related genes), inflammatory cytokines 
(TNF-α, IL-1, IL-6, IL-7, IL-17 and IL-23) and environmental factors (infections, 
mechanical stress, abnormal intestinal microbiota) play an important role [52].The 
complex interaction of these different factors can cause the activation of 
autoinflammation and autoimmunity. The onset of SpA typically occurs at young age 
(usually <45 years), early diagnosis is difficult mainly due to the lack of pathognomonic 
clinical feature or laboratory test. 
The average delay in diagnosis is estimated to be 8-11 years [75]. 
It is crucial to identify SpA patients and instituite treatments as early as possible after 
the onset of symptoms and in order to retard the radiological progression of the disease.  
Numerous studies in the literature tried to determine the mechanisms of SpA 
pathogenesis but it is still completely understood. Genetic, immunological and 
environmental factors play an important role in this disease.  
Genetic factors have long been recognized to play an important role in SpA 
pathogenesis; some familial aggregation studies have estimated that genetic risk factors 
contribute to 80-90% of the susceptibility to AS [77].  
The most studied genetic markers involved in AS and in PsA are located in the major 
histocompatibility complex (MHC) region but genome-wide association studies 
(GWAS) identified the genetic contribution of genes located in non MHC region [52]. 
HLA-B27, is an HLA class I surface protein encoded at the locus B of the MHC, on the 
short arm of chromosome 6. In 1969 was discovered its serological specificity [78] and 
four years later its association with SpA and related forms [79]. It was later observed 
that HLA-B27 is the major genetic risk factor in SpA. This association is present in 
many genetically diverse populations and across all major HLA-B27 subtypes [4]. 
HLA-B27 haplotype is present in 80-90% of AS patients and in 50-75% of patients with 
other SpA subtypes, the mechanisms about this association are partially understood [2].  
The HLA-B27 gene consist at least of 132 different alleles coding for 105 protein 
subtypes (HLA-B*27:01 to HLA-B*27:105). In Mediterranean populations, the most 
common subtypes associated with AS is HLA-B*27:02, in Chinese population is HLA-
B*27:04, in Caucasian is HLA-B*27:05 and in South Asian and Middle Eastern 
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population is HLA-B*27:07. Two subtypes, HLA-B27*06 and HLA-B27*09, seem to 
have no disease association [80]. 
The difference between the proteins encoded by the HLA-B27 alleles associated with 
SpA and those not associated with the disease included: structural conformation, the 
protein binding, the thermodynamic stability and the cell surface expression [81]. 
The main function of HLA-B27 is to present peptides derived from degradation of 
endogenous proteins to the surface of nucleated cells for recognition by CD8+ T-
lymphocytes. The basis of this hypothesis is the presence of the molecular mimicry 
between intracellular pathogens and self-antigens that may break self-tolerance leading 
to autoimmunity [82].  
Three main theories have been proposed to explain the pathogenic role of HLA-B27 in 
SpA: the presentation of arthritogenic peptides to autoreactive T lympochytes, the 
misfolding of HLA-B27 during its biosynetsis in the endoplasmic reticulum (ER) 
leading to an unfolded-protein response (UPR) and the cell surface HLA-B27 
homodimers hypoteses. The arthritogenic-peptide theory, which was formulated in 1990 
[83], is the most accepted pathophysiological framework for SpA. It is based on the 
premise of a molecular mimicry between pathogenic antigens (e.g., intracellular bacteria 
or an ubiquitous virus) and cartilage/bone-derived self-peptides that activate cytotoxic T 
lymphocytes (CTLs) after HLA-B27 antigen presentation [80]. This hypothesis has 
been supported by the finding of autoreactive HLA-B27-restricted CTLs that recognize 
peptides derived from intracellular bacteria as well as uninfected healthy cells in the 
synovial fluid of AS patients [84], and by the observation that gastrointestinal or 
urogenital infections can trigger SpA. The theory has not, however, been entirely 
corroborated by the identification of an autoimmune arthritogenic peptide [85] or in 
animal models [86,87]. The other two hypotheses argue in favour of the theory that 
HLA-B27 plays an autoinflammatory role in triggering the innate immune responses 
[52]. The misfolded HLA-B27 heavy chains tend to accumulate in the endoplasmic 
reticulum (ER), triggering ER stress, which leads to the activation of the unfolded 
protein response and the NF-κΒ pathway which, in turn, leads to the release of pro-
inflammatory cytokines, such as TNF-α, IL-1, IL-6, mainly by monocytes/macrophages, 
thus favouring the inflammatory process [88]. Animal disease models argue both in 
favour and against this hypothesis [89,90]. The cell surface HLA-B27 homodimers 
hypothesis is, instead, based on the observation that HLA-B27 homodimers produced at 
the cell surface bind to specific receptors expressed on NK cells, T-lymphocytes, and 
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myelomonotic cells producing an immunomodulatory effect [91]. This hypothesis has 
been supported by the finding that the number of NK and CD4+ T-cells expressing a 
receptor that recognizes HLA-B27 homodimers but not heterodimers is higher in HLA-
B27 positive patients [92]. 
HLA-B27 plays a critical role in the disease pathogenesis, recent studies suggest that it 
only accounts for 20-25% of the total heritability and 40% of the genetic risk. Fewer 
that 5% of HLA-B27 carriers in the general population develop SpA disease [93,94]. 
Other than HLA-B27 other MHC genes are involved in SpA: HLA-Cw6 is the most 
frequent allele associated to psoriasis, it is associated with more severe and early onset 
of both psoriasis and PsA [95]; HLA-B (B*40:01) appear to be associated with AS [96]. 
GWAS association studies have identified several SNPs in non-MHC genes strongly 
associated with SpA: endoplasmic reticulum aminopeptidase 1 (ERAP1), interleukin 23 
receptor (IL-23R), tumor necrosis factor (TNF) receptor 1 (TNFSF1A), the signalling 
molecule TNF receptor 1 associated death domain preotein (TRADD), the TNF 
superfamily cytokine (TNFSF15), interleukin 1 alpha (IL-1A), interleukin 1 receptor 2 
(IL-1R2), the vascular morphogenesis protein gene anthrax toxin receptor 2 (ANTXR2) 
and the innate immune receptor caspase recruitment domain family member 9 (CARD9) 
[97]. Other genes such as Familial Mediterranean Fever gene (MEFV) and signal 
transducer and activator of transcription 3 (STAT3) need additional confirmation. 
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1.6 Phatogenesis of Spondyloarthritis: autoimmune or 
autoinflammatory 
Immune-mediated inflammatory diseases (IMIDs) are characterized by a continuum 
ranging from autoimmunity to autoinflammation where innate immune response is 
activated by specific tissue triggers, such as micro-organisms or microtrauma [98]. 
Spa are considered to be polygenic IMID characterized by inflammation of the spine 
and peripheral joints, extra-articular manifestations and is not associated with typical 
autoimmune genes but displays polymorphisms in genes involved in innate immune 
recognition (CARD9) and cytokine signalling pathways (TNF-α, IL-1 and IL-23/IL-17 
axis) [99-102]. 
Spa disease is not associated with disease specific autoantibodies and does not show a 
female predominance, thus unmetting the classical features of autoimmune diseases.  
In the past, some studies have considered the SpA pathogenesis (AS in particular) with 
an adaptive immune response involvements; however in a recent view SpA is classified 
as a autoimmune disease where innate immune system play major role[103]. 
Clinical trials with B and T cell targeted therapies (abatacept, alefacept, efalizumab and 
rituximab) showed very modest therapeutic efficacy in SpA pointing out that the lack of 
classical autoimmune features explain the hypothesis that adaptive immune response are 
not primary in SpA [104].  
Due to the autoinflammatory origin of SpA, some studies have pointed the role of 
bacterial and local mechanical stress as triggers in the pathogenesis of the disease. Both 
factors are able to activate the innate immune responses. Genome-wide association 
studies and copy number variation (CNV) analyses identified SpA susceptibility genes 
that encode the components of innate immune system [94,105]. 
This evidence and the good clinical efficacy of the innate cytokine blockers suggest the 
contribution of innate immune system in SpA pathogenesis [106]. 
The activation and the regulation of the immune response are mediated by the cells of 
the innate immune system through the release of effector proteins know as cytokine 
such as IL-1β, TNF-α and other related members of this family. The IL-1 family 
contains nine genes with high sequence homology and the most studied members are 
IL-1α and IL-1β which are potent pro-inflammatory cytokines. IL-1β and TNF-α are 
produced by various types of immune cells; IL-1β can be secreted by all nucleated cells 
 21 
especially macrophages that recruit other immune cells to produce inflammation while 
TNF-α are produced by macrophages and T cells [104].  
An important cytokine with a broad regulatory role in the immune system is 
transforming growth factor-β (TGF-β). TGF-β is produced by and has effects on many 
different cells of the immune system, and plays fundamental roles in the regulation of 
immune responses during homeostasis, infection and disease.  
 
1.6.1 IL-1β 
Among the IL-1 family members, IL-1β seems to be the primary therapeutic target for a 
large number of inflammatory conditions. IL-1β is secreted as inactive precursor that is 
cleaved by Caspase-1 via inflammasome into an active cytokine [107]. IL-1β binds type 
I (IL-1RI) and type II (IL-1RII) specific receptor. IL-1RI is the main functional receptor 
for IL-1 signalling and after IL-1 binding undergoes a conformational change required 
for the recruitment of downstream signalling molecules that lead to activation of many 
transcription factors, such as NF-κB, AP-1, c-jun N-terminal kinase (JNK) and p38 
MAPK (Figure 4) [107,108]. 
 
 
Figure 4. IL-1β associated intracellular signaling pathways and downstream cellular targets and 
effects [109] 
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In animals model of arthritis both IL-1α and IL-1β can activate bone resorption 
osteoclast cells and induce other enzymes involved in joint destruction [110]. In vitro 
and in vivo models demonstrated that IL-1β is a strong stimulator of bone resorption 
because it upregulates the production of Receptor activator of nuclear factor kappa-Β 
ligand (RANKL) enhancing its activity and stimulating osteoclastogenesis [111].  
RANKL is the main cytokine involved in osteoclastogenesis and is a member of the 
membrane associated TNF ligand family, The RANKL-RANK receptor interaction 
stimulates several transcription factors that modulate osteoclast differentiation, 
activation, and survival thus leading the bone resorption [112]. In the inflammatory 
osteoclastogenesis IL-1β and TNF-α have an intimate relationship where many effects 
of TNF-α are upregulated by IL-1β. Experimental studies showed that blocking both IL-
1β and TNF-α cause a total arrest of bone resorption [112-114]. AS patients are 
characterized by an association of new bone formation and an increased bone 
resorption; these patients have an increased osteoporosis and vertebral fractures 
compared to healthy controls [115,116]. The inflammatory process and cytokine 
production are the main cause of osteoporosis in AS patients. Only few data are 
available regarding the efficacy of anti IL-1β in the treatment of AS; Anakira (IL-1R 
antagonist) was tested in a small prospective open-label trials in AS patients and did not 
have a better effect than an expected placebo response. In this study, anakira was not 
able to induce any improvement of sign and symptoms of AS and this study did not 
evaluate the bone loss or the bone new formation [117]. 
 
1.6.2 TNF-α 
TNF-α is a pleiotropic pro-inflammatory cytokine that play an essential role during the 
inflammatory response inducing the upregulation of adhesive molecules, lymphocyte 
activation, fibroblast proliferation and the production of other pro-inflammatory 
cytokines [118]. TNF-α is primarly produced as a transmembrane form (tmTNF) that 
can be cleaved by the TNF-α converting enzyme (TACE) into a soluble homotrimeric 
cytokine (sTNF). TNF-α exert its biological activities by binding two types of receptor: 
TNF receptor type I (TNFRI) and type II (TNFRII) (Figure 5). 
 23 
 
 
Figue 5. TNF-α associated intracellular signaling pathways and downstream cellular targets and 
effects [109]. 
 
These receptors bind with different affinities the sTNF-α and tmTNF-α; TNFRI 
(encoded by TNFRSF1A gene) binds both forms equally well and is the main receptor 
that mediates the proinflammatory response of TNF while TNFRII has a higher affinity 
for the tmTNF.  
The expression of multiple cytokine and immunoregulatory molecules are induced by 
the activation of both receptors [45].  
TNF-α is implicated in the pathogenesis of SpA, the analysis of sacroiliac biopsies have 
indicated the increases number of TNF expressing macrophages in AS patients [119]. 
Some studies have shown increased levels of TNF-α in blood of AS patients compared 
to subject with non-inflammatory back-pain or to healthy controls [120,121].  
TNF-α is encoded by TNFA gene which is located within the class III region of the 
MHC on chromosome 6 between the HLA-B and HLA-DR genes [122].  
Among the mechanisms that regulate TNF-α expression, several polymorphisms have 
been identified within the TNF promoter region relative to the transcription start site: -
1031 (T>C), 836 (C>A), -857 (C>T), -851 (C>T), -419(G>C), -376 (G>A), -308 
(G>A), -238 (G>A), -162 (G>A), and -49 (G>A). These variable regions have also been 
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shown to influence the differential TNF transcription and protein production between 
individuals [123,124]. 
The association between polymorphisms in the TNFA promoter region and SpA disease 
have been reported in different studies and different populations but the role of these 
polymorphisms in SpA patients is still unclear. Most studies have focused on Adenine 
(A) to Guanosine (G) transition at position -308 [125] and -238 [126].  
The decrease frequency of -238A and -308A alleles (high TNF-α secreting 
polymorphisms) found in some population have not been confirmed in all population-
based studies and meta-analyses. Two meta-analyses have detected no association 
between polymorphisms and AS susceptibility except for the AA genotype at -238 
position [127,128]. Other studies demonstrated an association of -308 G>A 
polymorphism with AS susceptibility [129,130]. Moreover, -308A allele has a 
protective role against AS and was associated with lower disease activity and severity of 
the disease [131]. 
 
1.6.3 TGF-β 
TGF-β is a potent cytokine and growth factor belonging to TGF-β superfamily together 
with bone morphogenetic proteins (BMPs), activins, nodal, and growth differentiation 
factors (GDFs) [132]. TGF-β exerts its pleiotropic action in multiple biological 
processes such as embryonic development, immune responses, inflammation and repair, 
cell proliferation and differentiation [133,134]. TGF-β is transcribed and translated as a 
small latent complex composed of active TGF-β and latency-associated peptide (LAP) 
which prevents the interaction of TGF-β with its specific receptor on the cell surface 
[135]. The TGF-β receptor is a tetrameric cell surface complex consisting of two 
transmembrane serine-threonine kinase pairs, type I (TβRI) and type II (TβRII) receptor 
kinase. Interaction of TGF-β with this receptor on target cells induces a intracellular 
signalling cascade by the phosphorylation of cytosolic Smad 2 and Smad 3 proteins 
[136,137]. Smad 2/3 forms a trimeric complex with Smad4 which then translocates into 
the nucleus where it binds SMAD-binding elements and recruits co-transcriptional 
factors to transactivate or repress target genes [138]. Smad 7, an inhibitory Smad, is 
induced by Smad2/3 complex as a feedback regulatory mechanism. In addition, TGF-β 
can activate numerous Smad independent signalling pathways such as the ERK, p38 and 
JNK mitogen-activated protein kinases, Rho-like GTPase and phosphatidylinositol-3-
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kinase/AKT pathways [139]. In the autoimmune inflammatory diseases the TGF-β 
effects are complex and difficult to predict also due to the clinical application of TGF-β 
inhibitors [140]. Several studies have demonstrated the presence of TGF-β in synovial 
tissue and synovial fluid of RA patients and higher expression of TβRII in rheumatoid 
synovial fibroblast [141,142]. 
Other study detected, in rheumatoid synovial fibroblast, an increased expression of 
TGF-β and TβRII. This expression correlates positively with clinical markers of disease 
activity depicted a strong correlation with TGF-β and inflammation [143]. 
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1.7 Phatogenesis of Spondyloarthritis:Calprotectin (S100A8/S100A9) 
Calprotectin is a member of the S100 protein family and is secreted primarly by 
neutrophilic granulocytes, monocytes and macrophages. Calprotectin is a calcium and 
zinc binding protein and is a heterocomplex composed by two different proteins 
S100A8 and S100A9 (MRP14/MRP8 or calgranulin A/B) [144], encoded by the 
S100A8/S100A9 gene located on chromosome 1q21 [145]. The presence of calcium 
induces conformational changes in the heterodimer, thereby allowing the binding of 
other proteins. Furthermore in the presence of calcium, MRP8/14 heterodimeric 
complexes may tetramerize into heterotetramers [146].  
The zinc-binding domains are involved in the antibacterial activity of calprotectin [147].  
The concentration of calprotectin in neutrophils is abundant and constitutes about half 
(30-60 %) of total cytosolic protein [148,149]; conversely calprotectin is not usually 
present in lymphocytes [148]. 
Calprotectin is also an important mediator of many regulatory functions such as 
chemotactic activity, deactivation of macrophages and inhibition of immunoglobulin 
synthesis. Elevated levels of calprotectin have been identified at sites of inflammation 
and in the extracellular fluid in patients with RA, cystic fibrosis, Sjogren’s syndrome 
and abscesses [149]. In experimental antigen-induced arthritis, MRP8 and MRP14 
significantly contribute to joint inflammation and leucocyte infiltration [150-153]. 
The concentration of calprotectin is known to be increased in plasma of patients with 
RA respect to those found in healthy individuals. Furthermore calprotectin was reported 
to be alevated in serum [154] and feces [155] and is an independent marker for 
radiographic spinal progression in axSpA [156]. 
Contradictory results have been found on the expression of calprotectin in SpA. 
Calprotectin was reported to be elevated in SpA as compared to the healthy controls and 
decrease rapidly and consistently upon effective treatment [154] while in another work, 
no differences in serum calprotectin between AS patients and healthy controls were 
found [155]. 
Huang and colleagues, demonstrated that calprotectin was to be elevated in both the nr-
axSpA and AS patients compared to healthy controls and correlated with CRP, ESR 
BASDAI and ASDAS indicating that it is a marker for inflammation signal. There is no 
difference between the nr-axSpA and AS patients in calprotectin levels [157]. Baseline 
calprotectin was higher in patients with more radiographic spinal progression, was 
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decrease upon tratement with TNF-α inhibitors and may represent a biomarker for 
clinical response [158,159].  
High levels of calprotectin have been found in synovial fluid from patients with PsA 
and RA respect to healthy controls [160].  
One of the most extra articular manifestations in SpA patients is IBD and fecal 
calprotectin was frequently used in the assessment of disease activity, response to 
treatment prediction of disease relapse or postoperative recurrence in IBD [161]. 
Elevated levels of fecal calprotectin at baseline in AS patients was the strongest 
predictor of the development of IBD, then calprotectin could be a potential biomarker to 
identified patients with AS at risk of developing IBD.  
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1.8 Phatogenesis of Spondyloarthritis:Matrix Metalloproteinases 
Metalloproteinases belong to a superfamily of zinc-dependent proteases known as 
metzincins. The superfamily of zinc-dependent proteases includes also: adamlysins 
(ADAMs), ADAMs with thrombospondin-like motifs (ADAMTSs), astacins, 
serralysins and pappalysins [162]. The term “matrix metalloproteinase” (MMP) defines 
these enzymes emphasizing the dependence of their activity on metal ions and their 
ability to degrade the structural proteins of the extracellular matrix. The regulated 
turnover of the molecules that compose the ECM is crucial for the interaction of 
individual cells with the surrounding environment, for proper physiological function, 
and for the development of the multicellular organisms [163]. The ECM present in the 
synovial membrane and cartilage is a key component of the joints. Far from being an 
inert structure, it undergoes continuous re-modeling which, in a homeostatic 
equilibrium, guarantees joints’ integrity. The modulation of cartilage re-modeling in 
SpA patients is due to inflammatory conditions where monocytes and macrophages 
release inflammatory molecules TNF-α, IL-1 and IL-6. The inflammatory mediators 
also induce the production of MMPs, the main enzymes involved in extra-cellular 
matrix degradation (Figure 6). 
 
Figure 6. Cartilage re-modeling in SpA pathogenesis [164]. 
We have recently demonstrated that metalloproteinases, MMP8 and MMP9 in 
particular, are produced by peripheral blood mononuclear cells if they are stimulated by 
calprotectin, the S100A8/S100A9 heterodimer [165]. This finding seems potentially 
relevant to the pathophysiology of arthritis since peripheral blood mononuclear cells 
represent a dynamic cellular population that can infiltrate the inflamed tissues where 
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they differentiate into inflammatory macrophages and thereby contribute to sustaining 
the inflammatory process. It has been reported that MMPs, and MMP3 in particular, are 
produced in response to cytokines in the joints, being more highly expressed in the 
synovial tissues of SpA patients than in peripheral blood mononuclear cells [166]. In 
view of these findings, studies have been performed in order to verify if serum MMPs 
level assessment can be used as a biomarker for diagnosing SpA, assessing disease 
severity, and predicting response to therapy with TNF-α inhibitors. The majority of 
studies focusing on MMP3 are in agreement with the finding of higher serum levels in 
SpA, in both AS and PsA subtypes, with respect to those in healthy controls, and these 
results are confirmed by a recent meta-analysis which demonstrated that increased 
serum MMP3 levels are associated to higher AS risk. However, the serum MMP3 levels 
related to the development and progression of AS were found to be conditioned by 
different geographical and genetic factors. In fact, at the ethnicity-stratified analysis, the 
MMP3 levels were higher in Asians and Caucasians than in African AS patients [167]. 
Although higher MMP3 baseline values appear to be correlated with the severity of SpA 
assessed biochemically (CRP) or using the BASDAI or BASFI severity indices, and 
seem to suggest peripheral joint involvement, the correlation between MMP3 serum 
levels and disease activity indexes is sometimes contrastive [164]. MMP3 together with 
CTX-II (C-terminal cross-linking telopeptide of type II collagen) seem to be particularly 
useful to predict radiographic progression of AS patients treated conventionally, 
outperforming over baseline CRP levels and BASDAI [168]. Besides MM3, MMP1, 
MMP2, MMP8 and MMP9 seem to be correlated with CRP in AS patients and MMP8 
and MMP9 seem to have a stronger association with BASDAI [169].  
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1.9 Pathogeneisis of Spondyloarthritis: Moncytes calcium-sensing cells 
SpA presents with multiple manifestations of inflammation that are due to complex 
causes. Many different cell components are involved in the development of 
inflammation, including neutrophils, mastocytes, T and B lymphocytes, and 
monocytes/macrophages. Activation of these cells leads to the production of cytokines 
and mediators responsible for inflammation. TNF-α has been shown to be the master 
element of inflammation in SpA.  
Monocyte cells are considered as a precursor for macrophages and dendrtic cells, 
moreover, monocytes are made of numerous subpopulations with distinct functions 
according to molecules expressed at their cell curface. Furthermore monocyte cells are 
able to differentiate in different cell type depending upon the stimuli they recived 
[170,171].  
Considering the role that monocytes have in chronic inflammatory disease, recent 
studies emphasized that monocytes could be interesting therapeutic targets [172,173].  
As well as in SpA, monocyte recruitment contributes to the pathogenesis of various 
other inflammatory disease such as chronic inflammatory rheumatism and RA in wich 
circulating monocytes recruitment in the joint could trigger inflammatory cascade [174]. 
The physiological functions of monocyte cells depend on calcium (Ca2+) signals; 
monocyte can detect variations of extracellular calcium through the calcium-sensing 
receptor (CaSR) activation. This process could induce the chemotactic response of 
monocytes to calcium concentrations in different sites of bone resorption or 
inflammatory sites [174]. At the intracellular levels Ca is a highly versatile signal that 
can regulate different cellular functions  
The Ca2+ signaling system operate in many different ways to regulate cellular processes 
that function over a wide dynamic range. Ca2+ play an important role in signal 
transduction pathways, where they act as a second messenger, in neurotransmitter 
release from neurons, in contraction of all muscle cell types, and in fertilization. Many 
enzymes require Ca2+ ions as a cofactor, those of the blood-clotting cascade being 
notable examples. Extracellular Ca2+ is also important for maintaining the potential 
difference across excitable cell membranes, as well as proper bone formation [175]. At 
any moment in time, the level of intracellular Ca2+ is determined by a balance between 
the “on” and “off” reactions (Figure 7) and cell survival is dependent on Ca2+ 
homeostasis, whereby the Ca2+ fluxes during the “off” reactions exactly match those 
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during the “on” reactions. Ca2+ that enters the cell from the outside is a principal source 
of signal Ca2+ during the “on” reaction. Cells use this external source of signal Ca2+ by 
activating various entry channels with widely different properties 
During the “off” reactions Ca2+ leaves the effectors and buffers and is removed from the 
cells by various exchangers and pumps. 
 
 
Figure 7. Calcium-signaling dynamics and homeostasis [175]. 
 
Ca2+ signals are highly organized in time and space in the form of transients, 
oscillations and cell-wide waves [176]. This array of Ca2+ signal modalities is thought to 
underlie regulation of physiological processes through effector specificity. These 
findings underscore the physiological importance of the spatial and temporal diversity 
of Ca2+ signaling and reveal the need for statistical analysis tools that encompass this 
diversity. 
Relative cellular Ca2+ levels are commonly measured as time lapse image sequences 
using fluorescent Ca2+ indicators, such as Fluo-4 that responds to Ca2+ binding with an 
increase of fluorescence intensity but not spectral shift. 
Fluo-4 is a fluorescent dye for quantifying cellular Ca2+ concentrations in the 100nM to 
1µM range. It was synthesized by substituting two fluorines for the two chlorine 
substituents in the fluorophore. It is easy to use and it can be loaded into cells either in 
membrane-soluble AM (acetoxymethyl) ester form or in salt form. Fluo-4 exhibits high 
Ca2+-dependent fluorescence enhancement, and a dissociation costant for Ca2+ 
(Kd(Ca2+)) of 345 nM, making it well suited for measuring physiologically important 
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Ca2+ changes in a wide range of cells. The excitation and emission wavelengths for 
Fluo-4 are 488 nm and 510nm respectively, making it suitable for use in flow 
cytometry, confocal laser scanning microscopy, microplate screening assays, or light 
microscopy when used in conjunction with standard fluorescein filter sets [177]. 
The time lapse image sequences which are obtained by Fluo-4 dye are often analyzed 
with user-defined Regions of Interest (ROIs) at sites determined to have fluctuations in 
fluorescence intensity, and the mean intensity within each ROI is measured as a 
function of time. 
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2. AIMS 
Spondiloarthritis is a family of chronic rheumatic disease predominantly affecting the 
axial skeleton, but also charachterized by the involvement of peripheral joints and 
tissues/organs outside the skeleton. The symptoms at the onset of disease, are not 
specific and this often determine a delay in diagnosis. The diagnostic process is often 
laborious because of the absence of pathognomonic clinical and/or laboratory findings. 
Diagnosis is supported by imaging and unfortunately not enough by biochemistry. The 
first aim of this study was to verify whether biochemical markers commonly used in 
clinical practice and the mRNA expression levels in mononuclear cells of inflammatory 
cytokines, calcium binding proteins and matrix metalloproteinases could be associated 
with the presence of  SpA (AS or PsA), and/or could be predicting anti-TNF-α treatment 
failure.  
The second aim is to investigate the role of circulating monocytes and of their 
intracellular calcium oscillations and if monocytes maintain or not their characteristic 
pattern of intracellular calcium behaviour when SpA is present.  
Specific aims were to investigate whether diagnosis of SpA (AS or PsA) and failure of 
response to anti-TNF-α drugs are associated with the followings markers: 
- Specific haematological and biochemical pattern of inflammation considering 
ESR and complete blood count, CRP, prealbumin, ALT, glucose, creatinine and 
uric acid;   
- mRNA expression levels in mononuclear cells of inflammatory cytokine (TNF-
α, IL-1β, TGF-β), S100 calcium binding protein (S100A8 and S100A9) and 
matrix metalloproteinases (MMP3, MMP8,MMP9); 
- Five SNPs (−1031 T>C, −857 C>T, −376 G>A, −308 G>A, −238 G>A), in the 
promoter region of TNFA, evaluated singely or as haplotypes;  
- Variations of intracellular calcium oscillations in circulating monocyte cells. 
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3. MATERIALS AND METHODS 
3.1 Sudied population 
In this study, was enrolled a cohort of 164 subjects belonging to the Veneto Region, a 
North-East Italian region, from January 2016 to December 2017.  
The cohort comprised 100 healthy controls (58 males and 42 females; mean 
age±standard deviation: 46.6±8.5) attending the Department of Transfusion Medicine 
University-Hospital of Padova (Italy) and 64 patients (39 males and 25 females; mean 
age±standard deviation: 39.5±13.2 years) affected by SpA and attending the 
Rheumatology Unit of the Department of Medicine-University-Hospital of Padova 
(Italy). 
Among patients, 26 (40.6%) had a definite diagnosis of AS, according to the modified 
New York criteria [10] and 38 (59.3%) had a diagnosis of PsA according to the 
CASPAR criteria [67]. The mean disease duration was 14 years (range 2–38 years).  
At enrollment, 57 patients (89%) were under therapy with anti- TNF-α agents (8 with 
Infliximab, 21 with Adalimumab, 20 with Etanercept, 4 with Golimumab, 3 with 
Ustekinumab and 1 with Secukinumab), of which 8 (14%) experienced in their clinical 
history, at least one or more switch of TNF-α inhibitor before entering the study. 
Among patients treated with anti- TNF-α agents, two patients had combined therapy 
with DMARDs and 7 patients were treated with DMARDs only. A subset of 8 patients 
started their therapy with anti-TNF-α agent at enrollment; for these patients a second 
sample was obtained after six months from the start of therapy. 
Patients were followed for at least 12 months after the beginning the anti-TNF-α agent. 
At least 10 months of treatment were considered to define a delayed response to TNF-α 
inhibitors. 
All patients patients gave fully informed written consent for the study, which was 
approved by the Local Institutional Ethic Committee (“Comitato Etico per la 
Sperimentazione, Azienda Ospedaliera di Padova”, protocol number: 3024P/13). 
 
3.2 Clinical Assessment 
All subjects attending the study were questioned about demographic (gender, age, place 
of birth, weight, height) and physiological (smoking, alcohol use) data. 
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Medical (age at diagnosis, laboratory tests at diagnosis, disease duration, 
axial/peripheral involvement, enthesitis, inflammatory back pain, articular and extra-
articular manifestations, pre-existing/current drug therapy) and family history (arthritis, 
psoriasis, other rheumatic diseases) data were also collected in SpA patients.The disease 
activity and physical functioning of patients were assessed with self-reported 
questionnaires: BASDAI, BASFI and ASDAS indexes. BASDAI includes six questions 
useful to investigate the intensity of pain; BASFI includes ten questions which explore 
the degree of difficulty encountered in carrying out specific activities of daily life and 
ASDAS is a composite index comprising subjective measures and laboratory 
parameters. The functional statement was also investigated with HAQ questionnaire 
which comprises 20 queastions about daily living activities. The axial involvement was 
investigated through the BASMI that indicates a condition that ranges from normal to 
the severely restricted spinal mobility (from 0 o 10 score). DAS index was used for the 
evaluation of the peripheral joint commitment through the count of tender/swollen joints 
and the evaluation of dactylitis and enthesistis. 
 
3.3 Haematological and biochemical indices 
For SpA patients and healthy donors, six blood samples were collected: two EDTA-K2 
tubes (6 ml blood each),one for mRNA expression analyses and the other one for 
monocyte cells isolations, two EDTA-K2 tubes (3 ml blood each), one of them for the 
determination of ESR and the complete blood count, the other one for genetic analyses; 
one lithium-heparin tube (3 ml blood) for the determination in plasma of glucose, uric 
acid, creatinine and alanine transaminase (ALT); one whole blood sample (4 ml) for the 
determination in serum of CRP and prealbumin. 
Complete blood count was performed using Sysmex XE-2100 analyser (Dasit, Milan, 
Italy) based on fluorescence flow cytometry analysis technology. 
TEST1 analyser (Alifax, SIRE Analytical System, Udine, Italy) which adopts a method 
based on capillary photometry-kinetic technology was used to ESR determination.  
Glucose, uric acid, creatinine and ALT levels were determined on Cobas 8000 modular 
analyser (Roche Diagnostics, USA) through the enzymatic- colorimetric assays widely 
used in routine testing and in particular: glucose: hexokinase method; creatinine: the 
Jaffé method; uric acid: uricase-peroxidase method; ALT: pyridoxal- 5-phosphate 
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method, according to procedure released by International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC).  
CRP and prealbumin were determined by immunometric assays on Dimension Vista 
1500 System (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA). 
 
3.4 Isolation of human peripheral blood mononuclear cells  
Human peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-K2 
peripheral blood from each enrolled subject by differential density gradient 
centrifugation (Histopaque®-1077, Sigma-Aldrich, Milano, Italy, F/H). This method is 
based on the different density of mononuclear cells compared to the other blood 
elements: PBMCs and platelets are concentrated over the layer of F/H while red blood 
cells (RBC) and granulocytes, characterized by an increased density compared to F/H, 
are collected on the bottom of the tube. After being the cells were washed twice with 
saline solution 1%  phosphate buffered saline (PBS) (Euroclone, MI, Italy) 
supplemented with 2% fetal calf serum (FCS) (Thermo Fisher Scientific, Waltham, 
MA, USA) to remove contaminating platelets and centrifuged at 1,200 rpm for 10 
minutes. PBMCs were then treated with a hemolysis solution (NH4Cl, KHCO3, EDTA 
Na4) for 10 minutes in order to remove RBCs cells, centrifuged at 1,200 rpm for 10 
minutes and used for the RNA extraction. 
 
3.5 Nucleic acids isolation  
Total RNA was extracted from PBMCs using High Pure RNA Isolation Kit (Roche 
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. 
The extraction method generate high-purity template and is based on the use of affinity 
spin columns. RNA was eluted in 60 µl of elution provided buffer. RNA concentration 
and purity were assessed for each sample by spectrophotometric measurement of the 
absorbance at the wavelenght of 260 nm and 280 nm (Nanodrop spectrophotometer, 
Thermo Fisher Scientific, Waltham, MA, USA). RNA concentration was 116.43±68.92 
ng/µl (mean±standard deviation) with a purity, calculated as 260/280 nm ratio, of 
2.31±2.06 (mean±standard deviation).  
Five hundred ng of total RNA were reverse transcribed into cDNA (Random primers 
and Superscript TM II RNasiH-Reverse Trascriptase, Waltham, MA, USA).  
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Genomic DNA, was extracted from 200 µl EDTA-K2 peripheral blood using the 
MagNA Pure96 System (Roche Diagnostics GmbH, Mannheim, Germany) according to 
manufacturer instructions. The extraction method is based on the binding affinity of the 
DNA to the glass (silica) surface of Magnetic Glass Particles. DNA was eluted in 100 µl 
of elution provided buffer. DNA concentration and purity were assessed for each 
sample by spectrophotometric measurement of the absorbance at the wavelenght of 260 
nm and 280 nm (Nanodrop spectrophotometer, Thermo Fisher Scientific, Waltham, MA 
USA). DNA concentration was 72.7±17.8 ng/µl (mean±standard deviation) with a 
purity, calculated as 260/280 nm ratio, of 1.86±0.13 (mean±standard deviation).  
 
3.6 Relative quantification analysis  
Relative quantification of S100A8, S100A9, MMP3, MMP8, MMP9, TNF-α, IL-1β and 
TGF-β1 genes were undertaken by Realt-Time PCR (qPCR) with ABI Prism 7900 HT 
(Thermo Fisher Scientific, Waltham, MA USA). Primers and fluorogenic probes for 
S100A8 (exon boundary: exon 1/exon 2), S100A9 (exon boundary: exon 1/exon 2), 
MMP8 (exon boundary: exon 5/exon 6) and MMP9 (exon boundary: exon 2/exon 3) 
analyses are reported in Table 2, 200 nM probe and 900 nM (S100A8 and S100A9) or 
500 nM (MMP8 and MMP9) each primer were used. Relative quantification of TNF-α, 
IL-1β and TGF-β1 and MMP3 was undertaken using the primers and probe set supplied 
by Thermo Fisher Scientific (Waltham, MA,USA, catalogue number 4331182, assay ID 
Hs00174128_m1 (TNF-α), Hs01555410_m1 (IL-1β), Hs00998133_m1 (TGF-β1), 
Hs00968305_m1(MMP3)). Relative quantifications were performed in a final volume 
of 20 uL with 33 ng cDNA. The reference gene, HPRT1 (Hypoxanthine-guanine 
phosphoribosyltransferase), was selected according to the method commonly used for 
internal control for quantitative gene expression analyses, and its expression was 
determined by commercially available HPRT1 primers and probe sets (Part Number 
4326321E, Thermo Fisher Scientific, Waltham, MA USA). S100A8, S100A9, MMP3, 
MMP8, MMP9, TNF-α, IL-1β and TGF-β1 and HPRT1 were analyzed in duplicate for 
each sample. PCR was run at 2 minutes at 50°C, 10 min at 95 °C, followed by 40 cycles 
of 15 seconds at 95 °C and 1 min at 60 °C. To determine the relative mRNA expression 
levels of all selected genes we used the comparative Ct method, a mathematical model 
that calculates changes in gene expression as a relative fold difference between an 
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experimental and a pool derived from 20 healthy blood donors used as calibrator 
sample.  
Gene Primers 
[Final concentration for S100s: 900nM] 
[Final concentration for MMPs: 500nM] 
Probe 
[Final concentration:200nM] 
S100A8 
F: 5’CTCTTGTCAGCTGTCTTTCAGAAGA3’, 
R:5’TTTCTCCAGCTCGGTCAACA3’,  
5’-FAM-AAGTCCGTGGGCATC-MGB3’ 
S100A9 
F: 5’CTCTTGTCAGCTGTCTTTCAGAAGA3’,  
R: 5’TTTCTCCAGCTCGGTCAACA3’ 
5’-FAM-AAGTCCGTGGGCATC-MGB3’ 
MMP8 
F: 5’CACTCCCTCAAGATGACATCGA3’ 
R:5’ACGGAGTGTGGTGATAGCATCA3’ 
5’FAM-CAAGCAACCCTATCCAACCTACTGGACCAA-TAMRA3’ 
MMP9 
F: 5’CCTGGGCAGATTCCAAACCT3’ 
R: 5’GCAAGTCTTCCGAGTAGTTTTGGAT3’ 
5’FAM-CTCAAGTGGCACCACCACAACATCACC-MGB3’ 
 
Table 2. Primers and fluorogenic probes for S100A8, S100A9, MMP8 and MMP9 analysis. 
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3.7 Genetic analysis  
3.7.1 TNFA gene analysis 
The genotype discrimination of five TNFA SNPs (-1031T>C, rs1799964; -857C>T, 
rs1799724; -376G>A, rs1800750; -308G>A, rs1800629; -238G>A, rs361525) was 
performed by a TaqMan dual probes allelic discrimination assay. Amplification was 
carried out with Realt-Time PCR instrument ABI Prism 7900 HT (Thermo Fisher 
Scientific, Waltham, MA USA). 
50 ng of genomic DNA were amplified in a reaction mix containing primers and probes 
at a final concentration specified in Table 2 and 1X TaqMan Universal Master Mix 
(Thermo Fisher Scientific, Waltham, MA USA), in a final volume of 20 µl. 
Primers and probes sequences and thermocycling conditions were shown in Table 3. 
 
TNFA 
SNPs 
Primers,  
[Final concentration, nM] 
Probes,  
[Final concentration, nM] 
Thermocycling 
Conditions 
-1031T>C 
rs1799964 
F:5’-AGGTGAGGCCGCCAGACT-3’,  
[900] 
R:5’-TCCTCAGAGCCGCTACATGTG-3’,  
[900] 
FAM:AGCTGAGAAGACGAAG (C), 
[200] 
VIC:AGCTGAGAAGATGAAG (T), 
[150] 
50 °C 2 min,   
95 °C 10 min,   
40 cycles 95°C 
15s,  
62 °C 1 min 
-857C>T 
rs1799724 
F:5’-GGTCCTGGAGGCTCTTTCACT-3’,  
[50] 
R:5’-AGAATGTCCAGGGCTATGAAAGTC-
3’, [900] 
FAM:CCCTGTCTTCGTTAAG (C), 
[200] 
VIC:CCCTGTCTTCATTAAG (T),  
[100] 
50 °C 2 min,  
95 °C 10 min,   
40 cycles 95°C 
15s,  
60 °C 1 min 
-376G>A 
rs1800750 
F:5’-CCCCTCCCAGTTCTAGTTCTATCTT-
3’, [300] 
R:5’-CCTATTGCCTCCATTTCTTTTGG-3’, 
[900] 
FAM:CTGTCTGGAAATTAGAAG(A), 
[100]  
VIC:CTGTCTGGAAG TTAGAAG 
(G), 
[150] 
50 °C 2 min,  
95 °C 10 min,   
40 cycles 95 
°C15s,  
60 °C 1 min 
-308G>A 
rs1800629 
F:5’-CAAAAGAAATGGAGGCAATAGGTT-
3’, [900] 
R:5’-GGCCACTGACTGATTTGTGTGT-3’,  
[900] 
FAM:AACCCCGTCCTCATG (A), 
[200] 
VIC:AACCCCGTCCCCATG (G), 
[150] 
50 °C 2 min,  
95 °C 10 min,   
40 cycles 95 
°C15s,  
56 °C 1 min 
-238G>A 
rs361525 
F:5’-AAATCAGTCAGTGGCCCAGAA-3’,  
[300] 
R:5’-GCATCAAGGATACCCCTCACA-3’,  
[900] 
FAM:CTCGGAATCAGAGCAG (A), 
[200]  
VIC:CTCGGAATCG GAGCAG (G), 
[200]  
50 °C 2 min,  
95 °C 10 min,   
40 cycles 95 
°C15s,  
60 °C 1 min 
TNFA: Tumor necrosis factor α, F: forward primer, R: reverse primer. 
 
Table 3. Primers, probes sequences and amplification profiles designed for five TNFA SNPs 
genotype discrimination. 
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3.7.2 HLA-B27 haplotypes detection 
HLA-B27 presence was determined in all subjects studied with an ABI Prism 7900 HT 
(Thermo Fisher Scientific, Waltham, MA USA).  
50 ng of genomic DNA were amplified in a reaction mix containing primers and probes 
at a final concentration specified in Table 4 and 1X TaqMan Universal Master Mix 
(Thermo Fisher Scientific, Waltham, MA USA), in a final volume of 20 µl. 
HLA-
B27 
Primers,  
[Final concentration, 900nM] 
Probes,  
[Final concentration, 250nM] 
Thermocycling 
Conditions 
Exon 2 
F:5’-CTACGTGGACGACACGCT-3’,  
R:5’-GCAAGGCCAAGGCACAGACT -
3’,  
5’ FAM-CGTGAGGTTCGACAGC-MGB 3’ 
50 °C 2 min,  
94 °C 7 min,  
50 cycles 92°C 20s,  
60 °C 1,10 min 
 
Table 4. Primers, probes sequences and amplification profiles designed for HLA-B27 analysis. 
 
3.8 Intracellular calcium fluxes analysis  
Intracellular calcium [Ca2+]i fluxes analysis were carried out  using an inverted 
epifluorescence microscope Nikon Eclipse Ti (Nikon Instruments, Amsterdam, 
Netherlands) using Fluo-4 AM (Thermo Fisher Scientific, Waltham, MA USA) high 
affinity Ca2+ indicators. As an illumination source, we used a mercury arc discharge 
lamp and selected excitation and emission wavelengths with an FITC filter cube (EX 
460-500 DM505 EM 510–560 nm). We used 40X1.30 oil objective (Nikon Instruments, 
Amsterdam, Netherlands) and, in order to minimize phototoxicity and photobleaching, a 
back-thinned electron multiplied CCD camera DS-U3 Digital sight (Nikon Instruments, 
Amsterdam, Netherlands). After the first minute, required to achieve optimal culture 
conditions, intracellular fluorescence was continuously monitored (5 frames/sec) for 12 
minutes.  
The fluorescence signal was quantified by measuring the mean pixel value of a 
manually selected cellular area for each frame of the image stack using the NIS-
Elements software (Nikon Instruments, Amsterdam, Netherlands). 
Monocyte cells were isolated from EDTA-K2 peripheral blood from 51 Spa patients and 
48 healthy controls using Human Monocyte Enrichment Cocktail (RosetteSep kit, 
StemCell Technologies, Vancouver, BC, Canada). Unwanted cells are targeted for 
removal with Tetrameric Antibody Complexes (TAC) recognizing non-monocyte cells 
and RBCs. Whole blood was incubated for twenty minutes with Human Monocyte 
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Enrichment Cocktail and monocyte cells were isolated by differential density gradient 
centrifugation as described above. 
106 monocytes were seeded on coverslips that had been inserted in six well culture 
plates and cultured for 24 hours in 2 mL of complete medium (RPMI, 10% FCS) 
(Thermo Fisher Scientific, Waltham, MA USA). 
Coverslips were incubated for twenty minutes  at 37°C with 5µM Fluo-4AM  in 
imaging buffer (IB) containing 137 mM NaCl, 5 mM KCl, 1.2 mM MgCl2 , 0.44 mM 
KH2PO4, 4.2 mM NaHCO3, 5 mM glucose, 20 mM HEPES pH 7.4. The cells were 
carefully washed two times and then incubated with IB at 37°C for ten minutes in order 
to allow Fluo-4 to stay inside the cells. 
The coverslip was placed in an appropriate chamber, added 1 mL of IB supplemented 
with 1mM CaCl2 and [Ca2+]i fluxes were analysed. 
 
3.9 “In vitro” experiments in Monocyte cells  
Monocyte cells were isolated from the buffy coat of healthy donors as described above 
and were seeded (3×106 cells per well) in six well culture plates and kept in continuous 
culture at 37 °C in a humidified atmosphere (5% CO2) for 24 hours. The cells were 
cultured in five different types of conditioned media: 1. RPMI 1640, 0.1% Gentamycin, 
1% L-Glutamine, 0% FCS, 2. RPMI 1640, 0.1% Gentamycin, 1% L-Glutamine 10% 
FCS, 3. RPMI 1640, 0.1% Gentamycin, 1% L-Glutamine, 10% of AS patients serum, 4. 
RPMI 1640, 0.1% Gentamycin, 1% L-Glutamine, 10% of PsA patients serum, 5. RPMI 
1640, 0.1% Gentamycin, 1% L-Glutamine, 10% of heathy subjects serum. Each 
experiment was performed at least in triplicate. Intracellular calcium fluxes were 
analysed as described above. 
 
3.10 Statistical analysis  
Mean, standard error (SE), standard deviation (SD) and 95% confidence interval (CI) 
were used as descriptive statistics for continuous data, while χ2 and Fisher’s exact tests 
were used for categorical data. The χ2 test, Fisher’s exact test, binary logistic regression 
analysis, Student’s t test for unpaired data, analysis of variance (ANOVA) and 
Bonferroni’s adjustement of p value for multiple testing were performed using Stata 
software, version 13.1 (StataCorp, Lakeway Drive, TX, USA). 
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4. RESULTS 
4.1 Studied population 
In this study, a total of 164 subjects from the Veneto Region (a North-east Italian 
region) were enrolled. These included 100 controls and a cohort of 64 patients with an 
established SpA diagnosis comprising 26 AS and 38 PsA. In statistical analyses, 
patients were evaluated as a single group (SpA) in comparison to controls, or AS and 
PsA groups were considered singly. Table 5 reports the demographic characteristics of 
controls and patients with results from the statistical analyses. Among PsA the 
percentage of females and mean age were higher with respect to AS and controls (Table 
5). Height did not differ between the studied groups while Body Mass Index (BMI) and 
weight were lower in AS patients.  
 
 Controls 
(n=100) 
AS 
(n=26) 
PsA 
(n=38) 
Statistics 
Gender M/F (% of F) 58/42 (42%) 19/7 (26%) 20/18 (47%) χ2=2.80,p=0.245 
Age mean±SD (years) 46±8 48±15 54±10** F=7.36,p=0.0009 
Weight mean±SD (Kg) 78.8±15.89 68.76±9.35* 75.38±11.11 F=5.40,p=0.0054 
Height mean±SD (cm) 171.75±7.72 171.76±7.40 169.26±8.34 F=1.48,p=0.2305 
BMI mean±SD (Kg/m2) 26.61±4.63 23.38± 2.89* 26.28±3.57 F=6.28,p=0.0024 
Bonferroni’s test for pairwise comparisons: *p<0.05 with respect to controls, **=p=0.001  with respect to 
controls. Significant p values are reported in bold face. AS: ankylosing spondylitis, PsA:psoriatic 
arthritis, M: male, F: female, SD: standard deviation, BMI: Body Mass Index. 
 
Table 5. Demographic characteristics in Controls, AS and PsA patients. 
 
4.2 Clinical characteristic of SpA patients  
The clinical characteristics of the two groups of patients are shown in Table 6. Family 
history of SpA, age at diagnosis and clinical symptoms were evaluated. Back pain and 
enthesitis were more frequent among AS, while peripheral arthritis, dactylitis and 
psoriasis were more frequent among PsA patients as expected. Extra-articular clinical 
manifestations, such as uveitis, IBD or urethritis/cervicitis were rare in both groups of 
patients.  
 
 
 43 
 AS (n=26) PsA (n=38) Statistics 
Family history of SpA, n (%) 9 (35%) 25(66%) χ2=6.02,p=0.014 
Age at diagnosis, mean ± SD (years)  36.5±13.96 41.65±12.48 F=2.39,p=0.1269 
Inflammatory back pain, n (%) 25(96%) 22(58%) χ2=11.58,p=0.001 
Peripheral arthritis, n (%) 9(35%) 38(100%) χ2=33.83,p=0.000 
Enthesitis, n (%) 13(50%) 29(76%) χ2=4.74,p=0.029 
Buttock pain, n (%) 22(84%) 10(26%) χ2=20.98,p=0.000 
Dactylitis, n (%) 3(11%) 8(21%) χ2=0.98,p=0.322 
Uveitis, n (%) 1(4%) 0(0%) χ2=1.48,p=0.223 
Psoriasis, n (%) 5(19%) 35(92%) χ2=34.98,p=0.000 
IBD, n (%) 3(11%) 0(0%) χ2=4.60,p=0.032 
Urethritis/Cervicitis/Diarrhoea, n (%)  2(7%) 7(18%) χ2=1.47,p=0.225 
Significant p values are reported in bold face. SpA: spondyloarthritis, AS: ankylosing spondylitis, PsA: 
psoriatic arthritis, SD: standard deviation, IBD: Inflammatory Bowel Diseases. 
 
Table 6. Clinical characteristics in AS and PsA patients at diagnosis. 
 
Outcome measures at diagnosis were also evaluated and reported in Table 7. Only the 
BASMI index significantly differed between groups, being higher among AS than PsA. 
 
 AS (n=26) PsA (n=38) Statistics 
ESR, mean ± SD (mm/hr) 27.23±19.72 31±11.62 F=0.92,p=0.3402 
CRP, mean ± SD (mg/L) 8.62±5.31 9.99±5.92 F=0.90,p=0.3465 
DAS, mean ± SD 3.22±0.96 3.74±0.99 F=4.29,p=0.0424 
BASMI, mean ± SD  3.27±1.806 1.31±1.58 F=21.07,p=0.0000 
BASFI, mean ± SD 5.52±1.90 4.62±1.90 F=3.45,p=0.0681 
HAQ, mean ± SD 0.96±0.52 0.91±0.53 F=0.16,p=0.6918 
BASDAI, mean ± SD 6.18±1.55 6.39±1.43 F=0.33,p=0.5649 
ASDAS-PCR, mean ± SD 3.12±0.64 2.98±0.48 F=1.02,p=0.3174 
Significant p values are reported in bold face. AS: ankylosing spondylitis, PsA: psoriatic arthritis, ESR: 
erythrocyte sedimentation rate, CRP: C-reactive protein, DAS: Disease Activity Score, BASMI: Bath 
Ankylosing Spondylitis Metrology Index, BASFI: Bath Ankylosing Spondylitis Functional Index, HAQ: 
Health Assessment Questionnaire, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, 
ASDAS: Ankylosing Spondylitis Disease Activity Score, SD: Standard Deviation. 
 
Table 7. Laboratory indices and outcome measures in AS and PsA patients at diagnosis. 
 
Patients enrolled in this study attended the Rheumatology Unit of the Department of 
Medicine- University-Hospital of Padova (Italy). All patients received NSAIDs or 
DMARDs therapy soon after diagnosis for variable time periods. In non-responders, 
anti-TNF-α was replaced to NSAIDs or DMARDs. Therefore at enrollment 7 PsA (not 
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AS) patients were on NSAIDs or DMARDs only, 2 patients (1 PsA and 1 AS) were on 
DMARDs and anti-TNF-α and 55 were on anti-TNF-α only. Among the 57 patients on 
anti-TNF-α, 8 cases switched anti-TNF-α agent twice (n=4), three (n=3) or four times 
(n=1) before the enrollment. A subset of 8 patients started their therapy with anti-TNF-α 
agent at enrollment; for these patients a second sample was obtained after six months 
from the start of therapy. Table 8 shows the number (and percentage) of patients treated 
with an anti-TNF-α agent, and the type of administered drug.  
The number of AS patients treated with a TNF-α inhibitor was higher with respect to the 
treated PsA patients.  
 
 AS (n=26) PsA (n=38) Fisher’s exact 
Therapy with anti-TNF-α agents, n (%) 26(100%) 31(82%) p=0.035 
Adalimumab, n (%) 13(50%) 8(21%) 
Etanercept, n (%) 7(27%) 13(34%) 
Golimumab, n (%) 0(0%) 4(10%) 
Infliximab, n (%) 6(23%) 2(5%) 
Ustekinumab, n (%) 0(0%) 3(8%) 
Secukinumab, n (%) 0(0%) 1(3%) 
p=0.002 
More than one anti-TNF-α n(%), (range) 3(11%),(1-3) 5(16%), (1-4) p=0.091 
Significant p values are reported in bold face. AS: ankylosing spondylitis, PsA: psoriatic arthritis,  
TNF-α = Tumor Necrosis factor alpha 
 
Table 8. Treatment with anti-TNF-α agents: patients affected by AS and PsA at study 
enrollement. 
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4.3 Haematological and biochemical indices in SpA patients 
Table 9 reports the mean and standard deviation of haematological and biochemical 
parameters evaluated in controls and in SpA patients at enrollment. The number of 
white blood cells (WBC) and polymorphonuclear cells (PMN) were higher in SpA 
patients with respect to controls, being the highest values recorded among AS, which 
also had significantly higher levels of haemoglobin with respect to controls. Moreover, 
in SpA patients, the number of lymphocytes, the glucose and CRP levels were higher 
with respect to controls, although there is no differences between the two SpA groups.  
 
 Controls (n=100) AS (n=26) PsA (n=38) Statistics 
WBC (x103/µL) 5.46±1.25 7.47±2.72** 6.42±1.83* F=15.91,p=0.0000 
Haemoglobin (g/L)  137.46±17.07 147.38±14.11** 142±13.95 F=4.34,p=0.0145 
Platelets (x103/µL)  239.81±55.38 256.42±76.43 260.79±57.60 F=2.07,p=0.1301 
PMN (x103/µL)  3.03±1.06 4.73±2.18** 3.75±1.39* F=17.14,p=0.0000 
Monocyte (x103/µL)  0.47±0.16 0.47±0.21 0.48±0.18 F=0.11,p=0.8973 
Lymphocyte(x103/µL) 1.83±0.49 2.13±0.75 2.06±0.65 F=3.97,p=0.0208 
Glucose (mmol/L) 4.93±0.86 5.30±1.13 5.44±1.20* F=4.21,p=0.0165 
Creatinine (µmol/L) 80±13.77 73.42±17.47 75.42±12.17 F=3.01,p=0.0519 
Uric acid (mmol/L) 0.30±0.07 0.29±0.08 0.28±0.07 F=0.55,p=0.5806 
ALT (U/L) 23.91±9.29 27.77±18.15 30.10±20.42 F=2.89,p=0.0583 
Prealbumin (mg/L)  284.34±39.72 295.28±57.58 286.86±47.90 F=0.60,p=0.5509 
CRP (mg/L) 3.07±2.88 4.79±4.39 4.18±4.35 F=3.09,p=0.0480 
Haematological and biochemical parameters are reported in terms of mean ± standard deviation. 
Bonferroni’s test for pairwise comparisons: *=p<0.05 with respect to controls; **=p<0.005 with respect 
to controls. Significant p values are reported in bold face. AS: ankylosing spondylitis, PsA: psoriatic 
arthritis, WBC: white blood cells, PMN: polymorphonuclear cells, ALT: alanine transaminase, CRP: C-
reactive protein. 
Table 9. Haematological and biochemical parameters in controls, AS and PsA patients at study 
enrollement 
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4.4 Cytokines and MMPs expression levels in PBMCs 
The expression levels of TNF-α did not differ between groups (Figure 8; F= 0.92, 
p=0.400).  
 
Figure 8. TNF-α mRNA expression (log2 fold increase) in PBMCs of Healthy controls 
(Controls), Psoriatic Arthritis patients (PsA) and Ankylosing Spondyilits (AS) patients. 
 
Among patients, the TNF-α expression levels were not associated with treatment type 
(DMARDs vs anti-TNF-α) (t=-0.5291; p=0.598), nor with any of the biochemical or 
clinical indexes considered. Interestingly TNF-α expression levels among patients were 
directly correlated with family history of SpA (Figure 9, t= -2.5386, p= 0.013). 
 
 
Figure 9. TNF-α mRNA expression (log2 fold increase) in PBMCs of SpA patients without or 
with Family history of SpA disease. 
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This finding prompted us to hypothesize a role for genetics in influencing TNF-α 
expression. For this reason five single nucleotide polymorphisms in the promoter region 
of TNFA gene were analysed, (-1031T>C, rs1799964; -857C>T, rs1799724; -376G>A, 
rs1800750; -308G>A, rs1800629; -238G>A, rs361525). None of the studied 
polymorphisms considered singly was correlated with TNF-α mRNA expression levels 
(F=1.15, p=0.331 for -1031T>C; F=0.40, p=0.672 for -857C>T; F=0.39, p=0.535 for -
376G>A; F=0.33, p=0.717 for -308G>A and F=0.00, p=0.977 for -238G>A). In a 
previous study [178] we demonstrated an association between the haplotype resulting 
from the combination of the rare TNFA -1031 C allele with the common TNFA -308 G 
allele with SpA. We verified whether the genotypes resulting from SNPs -1031T>C and 
-308G>A of the TNFA gene haplotypes combinations exerted any influence on TNF-α 
expression levels. Six genotypes were inferred (TG/TG, TG/TA, TG/CG, TA/TA, 
CG/TA, CG/CG) and grouped on the basis of our previous observation that the most 
frequent TNFA haplotype was -1031T/-308G while the protective TNFA haplotype was 
-1031C/-308G. Genotypes were grouped as follows: common homozygous (TG/TG), 
carriers of the protective haplotype (CG/TG, CG/TA and CG/CG), and others (TG/TA 
and TA/TA). TNF-α expression in PBMCs obtained from a series of 95 controls was 
found to be significantly reduced among carriers of the protective TNFA -1031C/-308G 
haplotype (Figure 10; F=3.276, p=0.042). This association between TNFA genetics and 
TNF-α expression was not confirmed in SpA patients (F=0.380, p=0.684). 
 
Figure 10.TNF-α mRNA expression (log2 fold increase) in PBMCs obtained from 95 controls 
grouped on the basis of genotypes derived from the TNFA -1031/-308 haplotypes combinations 
[178]. 
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Both MMP8 (F=0.19, p=0.825) and MMP9 (F=0.86, p=0.425) expression levels were 
not associated with diagnosis as depicted in Figure 11 
Similarly TGF-β1 (F=0.42, p=0.655) and IL-1β (F=0.85, p=0.427) varied independently 
from diagnosis. 
 
 
Figure 11. MMP8 (Panel A) and MMP9 (Panel B) mRNA expression (log2 fold increase) in 
PBMCs of Healthy controls (Controls), Psoriatic Arthritis patients (PsA) and Ankylosing 
Spondyilits (AS) patients. 
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4.5 Calcium binding proteins S100A8 and S100A9 expression levels in 
PBMCs 
The expression levels of S100A8 were found to be significantly lower in PsA patients 
with respect to controls (Figure 12; F=3.29, p=0.039), while S100A9 were not (F=1.94, 
p=0.147)  
 
Figure 12. S100A8 (Panel A) and S100A9 (Panel B) mRNA expression (log2 fold increase) in 
PBMCs of Healthy controls (Controls), Psoriatic Arthritis patients (PsA) and Ankylosing 
Spondyilits (AS) patients. 
 
Both S100A8 and S100A9 were not correlated with the severity indexes of disease 
BADAI, BASFI, BASMI, ASDAS-PCR, DAS and HAQ nor with metabolic and organ 
function indices. By contrast both S100A8 and S100A9 were significantly correlated 
with circulating inflammatory cells and S100A8, not S100A9, with the inflammatory 
indices ESR and CRP (Table 10). 
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S100A8 S100A9 
WBC (x103/µL) R=0.2121,p=0.095 R=0.1518, p=0.234 
Haemoglobin (g/L) R=-0.1466, p=0.251 R=-0.0387, p=0.763 
Platelets (x103/µL) R=0.0557, p=0.664 R=-0.0047, p=0.970 
PMN (x103/µL) R= 0.3150, p=0.011 R=0.2913, p=0.020 
Lymphocyte (x103/µL) R=-0.1646, p=0.197 R=-0.2800, p=0.026 
Monocyte (x103/µL) R=0.2935, p=0.026 R=0.3368, p=0.010 
ESR (mm/hr) R=0.3202, p=0.010 R=0.1631, p=0.201 
CRP (mg/L) R=0.2679, p=0.033 R=0.1699, p=0.183 
Significant p values are reported in bold face. WBC: white blood cells, PMN: polymorphonuclear cells, 
ALT: alanine transaminase, ESR: Eritrocyte sedimentation rate, CRP: C-reactive protein. 
Table 10.Correlations between the expression levels of calcium binding proteins S100A8 and 
S100A9 (log2 fold increase) and inflammatory cells and inflammatory indices in PBMCs of 
patients with SpA (n=64) 
 
 
4.6 Intracellular calcium fluxes in Healty subjects and SpA patients 
Monocytes recruitment at joint inflammatory sites plays a key role in the inflammatory 
cascade and in joint destruction. It has been recently pointed out that calcium signalling 
in circulating monocytes regulates their chemotaxis and cytokines production. With this 
in mind, in this study we verified whether the pattern of intracellular calcium 
oscillations differs between healthy subjects (n=48) and patients with SpA (n=51). To 
do this, blood monocytes were first isolated by negative selection and then used to 
ascertain intracellular calcium oscillations by epifluorescence microscope analysis. 
Monocytes obtained from healthy blood donors had evident and frequent intracellular 
calcium oscillations, while monocytes obtained from SpA patients did not. Figure 13 
shows individual cellular data from representative experiments from 4 controls and 4 
SpA patients.  
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Figure 13. Intracellular calcium fluxes ([Ca2+]i) of monocyte cells from Healthy controls 
(Controls) and SpA patients (SpA). 
 
For any individual experiment, each referred to any individual case and control, the 
number of monocytes exhibiting intracellular calcium oscillations profile with respect to 
 52 
the whole number of cells examinated was calculated and expressed as percentage (% of 
cells). Figure 14 shows the results obtained in healthy controls (Controls), patients with 
PsA or with AS. AS patients had a significant lower percentage of active monocytes 
with respect to controls (F=6.15, p=0.003).  
 
 
Bonferroni’s test for pairwise comparisons: *=p<0.005 with respect to controls; 
Figure 14. Percentage of monocyte cells (% of cells) with intracellular calcium oscillations in 
Healty controlos (Controls) in Psoriatic Arthritis patients (PsA) and Ankylosing Spondyilits 
(AS) patients. 
 
We then evaluated considering only the cells exhibitng intracellular calcium 
oscillations, the frequency of the oscillations which was expressed as 
oscillations/minute. No difference was observed between patients and controls (F=0.03, 
p=0.973). 
 
The percentage of cells with intracellular calcium oscillations in SpA patients (n=51) 
was not correlated with the severity clinical indices BASDAI, BASFI, BASMI, 
ASDAS-CRP, DAS and HAQ as detailed in Table 11, nor with the biochemical indices 
of inflammation, namely circulating PMN, lymphocytes, monocytes, CRP and ESR, as 
detailed in Table 12. 
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SpA patients 
 
Coefficent SE 95% CI p-Value 
BASDAI -0.094 0.178 -0.454 to 0.266 0.601 
BASFI 0.107 0.132 -0.159 to 0.373 0.421 
BASMI -2.128 1.336 -4.823 to 0.565 0.118 
ASDAS-CRP -5.615 4.444 -14.577 to 3.346 0.213 
DAS 3.214 2.592 -2.013 to 8.441 0.222 
HAQ -0.756 4.546 -9.925 to 8.412 0.869 
Significant p values are reported in bold face. BASDAI: Bath Ankylosing Spondylitis Disease Activity 
Index, BASFI: Bath Ankylosing Spondylitis Functional Index, BASMI: Bath Ankylosing Spondylitis 
Metrology Index, DAS: Disease Activity Score, ASDAS: Ankylosing Spondylitis Disease Activity Score, 
CRP: C-reactive protein, HAQ: Health Assessment Questionnaire, SE: Standard Error, CI= Confidence 
Interval. 
 
Table 11. Multiple regression analysis considerenig the percentage of cells with intracelluar 
calcium oscillations as dependent variable and the clinical indices as predictor variables.  
 
 SpA patients 
 Coefficent SE 95% CI p-Value 
Age 0.364 0.238 -0.120 to 0.849 0.135 
Gender 7.459 6.579 -5.912 to 20.829 0.265 
BMI 1.513 0.839 -0.192 to 3.218 0.080 
WBC(x103/µL) -9.747 20.115 -50.627 to 31.133 0.631 
PMN (x103/µL) 10.380 20.427 -31.134 to 51.894 0.615 
Lymphocyte (x103/µL) 8.155 20.615 -33.740 to 50.051 0.695 
Monocyte (x103/µL) 3.925 24.545 -45.958 to 53.808 0.874 
CRP (mg/L) -0.425 0.923 -2.302 to 1.450 0.648 
ESR (mm/hr) -0.175 0.260 -0.705 to 0.354 0.506 
Constant -33.840 20.448 -75.397 to 7.716 0.107 
Significant p values are reported in bold face.WBC: white blood cells, PMN: polymorphonuclear cells, 
CRP: C-reactive protein, ESR= Eritrocyte sedimentation rate. SE: Standard Error, CI= Confidence 
Interval. 
 
Table 12. Multiple regression analysis considering the percentage of of cells with calcium 
oscillations as dependent variable and biochemical indices of inflammation as a predictor 
variables. 
 
 
The percentage of cells exhibiting a calcium oscillation was then analysed in the light of 
peripheral joint involvement (peripheral arthritis, enthesitis, dactylitis), psoriasis and 
presence or absence of buttock pain or back pain. Table 13 reports mean values with 
standard errors and a statistical analysis of data (student’s t test). Uveitis and IBD were 
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not evaluated due to the low number of patients with any of these conditions. The 
proportion of cells exhibiting an intracellular calcium oscillations were significantly 
reduced among patients without dactylitis or psoriasis, and slightly reduced among 
patients with buttock pain. 
 
 SpA patients 
Clinical condition Absent Mean±SE Present Mean±SE Statisitcs 
Peripheral arthritis 10 14.8±3.9 40 23.6±2.5 t=-1.61, p=0.114 
Enthesitis 15 19.61±3.52 35 22.82±2.81 t=-0.66, p=0.514 
Dactylitis 41 19.59±2.29 9 32.16±5.69 t=-2.26, p=0.028 
Psoriasis 16 14.18±3.09 34 25.47±2.74 t=-2.49, p=0.016 
Buttock pain 27 25.52±3.06 23 17.55±3.06 t=1.83, p=0.074 
Back pain 14 21.38±4.61 36 22.04±2.55 t=-0.13, p=0.895 
Significant p values are reported in bold face. SE: Standard Error 
Table 13. Student’s t test for unpaired data considering the absence and the presence of 
peripheral joint involvement psoriasis, buttock pain and back pain and the percentage of 
monocyte cells with intracellular calcium oscillations. 
 
Since the reduced proportion of cells with calcium oscillations was correlated with 
features that characterize AS with respect to PsA, binary logistic regression analysis 
was performed in order to verify whether cells with calcium oscillations were 
independently correlated with diagnosis. In the analysis, AS diagnosis was considered 
the outcome variable, PsA diagnosis was the reference, buttock pain, dactylitis, 
psoriasis, HLA-B27 and the percentage of cells with calcium oscillations were 
independent variables (Table 14). Absence of psoriasis and presence of buttock pain 
were independently correlated with AS diagnosis, while cells with calcium oscillations 
were not. This indicates that this latter variable is not per sè and index of AS, but this 
does not exclude its potential pathophysiological role. 
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 Coefficent SE 95% CI p-Value 
Age 0.060 0.059 -0.057 to 0.178 0.315 
Gender -1.267 1.176 -3.572 to 0.037 0.281 
BMI -0.474 0.267 -0.997 to 0.049 0.076 
Buttock pain 2.355 1.111 0.177 to 4.534 0.034 
Dactylitis 2.355 1.573 -0.727 to 5.438 0.134 
Psoriasis -2.542 1.077 -4.653 to -0.430 0.018 
% of cells -0.041 0.044 -0.127 to 0.045 0.348 
HLA-B27 0.085 1.096517 -2.064 to 2.235 0.938 
Constant 10.387 5.946946 -1.268 to 2.043 0.081 
Significant p values are reported in bold face. BMI: Body Mass Index; SE: Standard Error; CI= 
Confidence Interval. 
 
Table 14. Logistic regression analysis considering AS diagnosis as the outcome variable 
buttock pain, dactylitis, psoriasis, percentage of cells with calcium oscillations (% of cells), 
HLA-B27 age and gender as predictors. 
 
 
Since all 51 patients SpA were under treatment, we verified whether variations in cells 
with calcium oscillations were correlated with the drug type used. Values found in 
patients under DMARDs treatment (n=6, Mean±SE: 22.928±6.462) were not different 
form values of patients under anti-TNF-α (n=44, Mean±SE: 21.709±2.394), (student’s t 
test for paired data: t= 0.17, p= 0.861). This result was further confirmed in the subset of 
8 patients who had a replicated analysis before and after 6 months from the beginning of 
anti-TNF-α therapy (student’s t test for paired data: t = 0.21, p=0.833). 
The percentage of cells with calcium oscillations was then correlated with the metabolic 
and organ function biochemical indices, namely glucose, creatinine, ALT, uric acid and 
with age and BMI. No significant colleration was found when cases and control were 
considered overall, while significant correlation were recorded among patients between 
the percentage of cells with calcium oscillations and age (R=0.3808, p= 0.006), BMI 
(R= 0.3714, p=0.007), creatinine (R=-0.3029, p=0.032) and with uric acid (R= -0.3415, 
p=0.015). Multiple linear regression analysis performed considering SpA patients 
confirmed the significant and independent association between cells with calcium 
oscillations and BMI and uric acid (Table 14) 
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 SpA patients 
 Coefficent SE 95% CI p-Value 
Age 0.206 0.180 -0.157-0.569 0.259 
BMI 1.455 0.590 0.266-2.644 0.018 
Creatinine (µmol/L) -0.272 0.155 -0.585-0.040 0.086 
Uric acid (mmol/L) -70.071 34.350 -139.255--0.886 0.047 
Significant p values are reported in bold face. BMI: Body Mass Index; SE: Standard Error; CI= 
Confidence Interval. 
 
Table 14. Multiple regression analysis considering the percentage of percentage of cells with 
calcium oscillations (% of cells), as dependent variable and Age, BMI, Creatinine and Uric Acid 
as a predictor variables. 
 
We then evaluated whether the variations found in cell with calcium oscillations among 
patients were correlated with the expression levels of inflammatory cytokines, S100 
proteins and MMPs. While in control subjects no correlation was found (Figures 15 and 
Figure 16, left panels), the percentage of cell with calcium oscillations was significantly 
correlated with the expression levels of TNF-α and IL-1β among patients (Figure 15, 
righ panels), but not with S100 proteins, MMPs or TGF-β (Figure16, right panels). 
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Figure 15. Correlation among monocyte cells with intracellular calcium oscillations (% of cells) 
and TNF-α, TGF-β, IL-1β mRNA expression levels (log2 fold increase) in PBMCs of Healthy 
Controls (Controls) and SpA patients (SpA).  
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Figure 16. Correlation among percentage of monocyte cells with intracellular calcium 
oscillations (% of cells) and S100A8, S100A9, MMP8, MMP9 mRNA expression levels (log2 
fold increase) in PBMCs of Healthy Controls (Controls) and SpA patients (SpA).  
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4.7 Healthy subject serum induces intracelluar calcium oscillations in 
human monocytes 
The observed disease-related pattern of cell with calcium oscillations might be 
consequent to intrinsic monocytes alterations and/or to soluble blood mediators. To 
verify this latter hypothesys we performed in vitro experiments using three healthy 
donors blood monocytes which were conditioned for 24 hours with FCS or with human 
serum pools obtained from healthy subjects (n=3), from patients with AS (n=3) and 
from patients with PsA (n=3). At the end of the conditioning period, intracellular 
calcium oscillations of monocytes were analysed and the percentages of cells with 
intracellular calcium were calculated as described above. Figure 17 shows the obtained 
results. Intringuinly the percentage of cell with calcium oscillations significantly 
increased in the presence of healthy human sera, but not in the presence of disease sera 
(Kruskal Wallis test: p=0.038), supporting the hypothesis that in SpA patients soluble 
mediators are released into the bloodstream that dampen monocytes intracellular 
calcium oscillations. This finding poses the basis for the potential identification of new 
blood biomarkers of disease.  
 
 
Figure 17. Percentage of monocyte cells (% of cells) with intracellular calcium oscillations in 
healty blood donors cultured in the absence or presence of 10% FCS, 10% of Healthly controls 
(Control), 10% of Psoriatic Arthritis patients (PsA) and 10 % of Ankylosing Spondyilits (AS) 
patients serum. 
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4.8 Therapy effects 
The expression levels of the studied molecules were evaluated taking into account the 
type of drug used for treatment. Patients were then subdivided according to treatment 
with DMARDs only (n=7), Adalimumab (n=21) or Etanercept (n=20); the remaining 
patients under treatment with Golimumab, Infliximab, Ustekimumab and Sekukimumab 
were grouped all together due to their low number (n=15).  
Table 15 reports the results of statistical analysis (one way ANOVA). Type of treatment 
did not influence any of the studied molecules.  
 Statistics 
IL-1β F=1.21, p=0.313 
TGF-β F=0.60,p=0.616 
TNF-α F=0.20,p=0.896 
MMP8 F=0.23,p=0.877 
MMP9 F=0.93,p=0.430 
S100A8 F=0.53,p=0.663 
S100A9 F=0.39,p=0.760 
% of cells F=0.27,p=0.850 
 
Table 15. IL-1β, TGF-β, TNF-α, MMP8, MMP9, S100A8, S100A9 mRNA expression levels 
(log2 Fold increase) and percentage of monocyte cells with intracellular calcium fluxes (% of 
cells) in the response to treatment with DMARDs and anti- TNF-α therapy.  
 
Moreover, none of the studied molecules expression levels were modified by therapy 
also considering the subset of 8 patients for whom results were available before and 
after six months of anti TNF-α therapy (Table 16 shows Student’s t test results for 
paired data). 
 Student’s t test p-Value 
IL-1β t=0.6085 0.562 
TGF-β t=0.2326 0.822 
TNF-α t=-0.7228 0.493 
MMP8 t=0.4725 0.650 
MMP9 t=1.1111 0.309 
S100A8 t=0.4329 0.678 
S100A9 t=1.2433 0.253 
 
Table 16. IL-1β, TGF-β, TNF-α, MMP8, MMP9 S100A8, S100A9 mRNA expression levels 
(log2 Fold increase) in the absence or presence of anti-TNF-α therapy.  
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5. DISCUSSION and CONCLUSIONS 
Spondyloarthritis comprises two main diseases, AS and PsA, that primarly involve the 
spine, but they can also affect peripheral joints and tissues/organs outside the skeleton, 
like eyes, skin and intestine. The symptoms that patients refer at the onset of disease, 
mainly back pain, are not specific and this often determine a delay in diagnosis on the 
one hand and repeated cycles of therapy with anti-inflammatory agents. The delayed 
diagnosis with a consequent delay in appropriate treatments might associate with 
disease progression that cause irreversible joint damage. Diagnosis is supported by 
imaging and unfortunately not enough by biochemistry. In fact no specific blood 
biomarkers are available for these diseases. Moreover, despite the intensive 
inflammatory process involving sacro-ileal joints, the common blood inflammatory 
indexes, e.g. CRP and ESR, remains within the reference ranges or are only modestly 
altered. These considerations have prompted the research of new potential biomarkers 
that may help and support diagnosis and monitoring. Among these a special attention 
has been posed on the circulating levels of metalloproteinases, mainly on MMP3, and 
on emerging inflammatory proteins, like the calcium binding proteins S100A8 and 
S100A9 and their derived complex calprotectin. In this study we focused on circulating 
mononuclear cells as key players of the inflammatory process of SpA. In fact 
macrophages infiltrating the inflamed joints derive from circulating monocytes and 
contribute to the process of tissue destruction be expressing not only inflammatory 
cytokines, like TNF-α or IL-1β, but also enzymes causing tissue destruction and 
remodelling, like metalloproteinases. With this in mind we first evaluated whether 
circulating mononuclear cells have different mRNA transcription levels of the 
inflammatory cytokines TNF-α, IL-1β and TGF-β. When compared to controls, AS and 
PsA patients had similar cytokines expression levels in their circulating mononuclear 
cells. This finding was in part unexpected, since increased protein levels have been 
reported in these patients and the role of these cytokines, mainly TNF-α and IL-1β, in 
disease pathogenesis is well established and supported by the dramatic efficacy of anti-
TNF-α therapy. Our unexpected findings might be explained considering that very small 
variations in the expression levels of mRNA, not traceable with the actual quantitative 
assay sytems, can result in wider variations of the encoded proteins; moreover 
mononuclear cells might enhance the expression levels of inflammatory cytokines only 
when homed at the joint tissue sites. 
 62 
Despite the lack of association between cytokines expression levels and disease 
diagnosis, the variations of TNF-α, TGF-β and IL-1β were correlated each other in 
controls and in SpA patients, suggesting that these inflammatory pathways share 
common drivers and probably influence each other. For the relevance of TNF-α in SpA, 
we analysed in more depth this cytokine, by evaluating in our series of patients whether 
its expression was associated with the clinical indixeses of disease activity, the extra-
spine lesions, the biochemical inflammatory and metabolic indices, but none of those 
analysed was found to influence TNF-α results. By contrast a significant correlation was 
detected between TNF-α and family history of SpA, being higher expression levels 
recorded among patients with a positive than in those with a negative history. This 
intringuing finding further supports the potential role of TNF-α in disease risk and 
suggests a genetic search. TNF-α is encoded by TNFA gene which is located in close 
proximity of the MHC locus in chromosome 6 between the HLA-B and HLA-DR 
genes, which carries well known predisposing alleles for AS, the HLA-B27, and for 
PsA, the HLA-Cw6. Some TNFA variants, which might be in linkage with HLA 
predisposing alleles, might be implicated in disease pathogenesis. We verified five 
single nucleotide polymorphsims of the TNFA promoter, that result in haplotypes that 
might influence TNF-α expression. As hypothesized the haplotype resulting from the 
combination of the rare TNFA -1031C and TNFA -308G alleles was significantly 
associated with reduced TNF-α expression levels in mononuclear cells of healthy 
controls. This finding supports our previous observation that this haplotype has a 
protective role for SpA [178]. However in patients TNFA genetics did not associate 
with TNF-α expression, suggesting that the role of genetics in the regulation of mRNA 
expression can be masked by other disease related factors, like other cytokines or other 
triggers of the TNF-α pathway.  
On the basis of the above results, TNF-α, TGF-β and IL-1β appear of no clinical utility 
in SpA diagnosis, nor in the stratification of disease severity. We therefore moved our 
attention to other potential inflammatory biomarkers, choosing the metalloproteinases 
MMP8 and MMP9 for their potential role in SpA. In this approach we did not forget 
another metalloproteinase, MMP3, which was reported as the most promising 
diagnostic tool for SpA, both at serum protein level and as mRNA expression level. 
MMP3 mRNA expression was never measurable in both patients and controls (data not 
shown). The discrepancy of our results with previous data in the literature might be 
explained considering that MMP3 protein was described as increased in serum, while 
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increased transcripts have been described in synovial fluid or tissues. Although MMP3 
and mononuclear cells are both potentially involved in disease pathogenesis, this does 
not necessarily imply that this metalloproteinase would be produced directly by 
mononuclear cells. Other MMPs could be implicated, and we focused on MMP8 and 
MMP9 for which very few data are present in the literature. However, although both 
expressed at measurable levels in circulating mononuclear cells, they did not vary 
between controls and patients, nor they were related to disease clinical activity indices. 
An emerging concept in inflammatory joint diseases is the role played by intracellular 
calcium as a trigger for the release of inflammatory molecules and of the related 
calcium binding inflammatory S100 proteins. Two members of this protein family 
appear of particular relevance: S100A8 and S100A9, which mRNA and protein 
expression levels was shown to be increased in the synovial fluid and in blood of 
patients with rheumatoid arthritis. They appear involved in joint destruction, probably 
also because they are inducers of metalloproteinases, including MMP8 and MMP9. 
S100A8 and S100A9 proteins are both expressed by mononuclear cells and, based on 
this premise, we verified whether their expression by circulating mononuclear cells is 
altered in SpA. While S100A9 expression did not vary, the expression of S100A8 was 
reduced in PsA patients as compared to controls. This finding is hard to be explained, 
taking also into account that among patients S100A8 expression levels were correlated 
with the inflammatory indices CRP and ESR, and with the number of blood 
inflammatory cells, namely PMN and monocytes. However, these correlations might 
spurious and consequent to the observation that PMN, CRP and ESR values were higher 
in AS than in PsA, as S100A8. The main question is why S100A8 is reduced. One of 
the mechanisms underlying S100A8 expression might be variations in intracellular 
calcium, which regulates several biological processes of the cells. Intracellular calcium 
balance is tightly regulated by transporters expressed both at cell membrane and 
mitochondrial membrane [179]. Alterations in intracellular calcium might be 
characterized by increased and constant accumulation of the ion, increased frequency in 
its oscillations, but also the opposite might also occur, i.e. decreased intracellular levels 
and/or frequency of oscillations. These alterations may evoke different biological 
effects, which depend on cell type and cell context. It has been recently reported that 
monocytes from patients with arthritis might have alterations in intracellular calcium 
due to an altered expression of the calcium sensing receptor (CaSR) [174]. On the other 
hand the ORAI Ca2+ channels, also expressed by monocytes and found to be reduced by 
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bacterial products, have been suggested to play a role in arthritis. We verified whether 
circulating monocytes maintain or not their characteristic pattern of intracellular 
calcium behaviour when SpA is present. Our findings clearly demonstrate that 
monocytes from patients with SpA, but mainly with AS, loose their typical intracellular 
calcium pattern. In other words, while the majority of monocytes from controls 
maintained in culture for 24 hours show regular calcium oscillations, only a minority of 
monocytes from AS patients maintain this pattern, while the majority of them do not 
show regular calcium oscillations. This finding requires some comments: 1. the reduced 
number of monocytes with intracellular calcium oscillations might be the expression of 
a differentiation shift of monocytes towards the dendritic cell or the mMDSC 
phenotypes. In fact, as previously demonstrated by us, these cellular subsets of the 
monocyte population present reduced or even absent intracellular calcium fluxes [180]. 
The role of MDSC as contributors in arthritis and psoriasis is actually an emerging 
concept: Cao et al. described in psoriasis increased monocytic MDSC that produce 
increased amounts of IL23, IL-1β and the Chemokine (C-C motif) ligand 4 (CCL4), and 
a de-regulated immunosuppressive loop in this disease has been suggested [181], while 
Zhang et al. supported the potential pathophysiological role of these 
immunosuppressive cells demonstrating in the animal model their role in bone erosion 
[182]. In our series of patients, not in controls, an association between the percentage of 
monocytes with intracellular calcium oscillations and the expression levels of TNF-α 
and IL-1β was effectively recorded, but this association was inverse, a progressive 
reduction of cytokines expression and the percentage of monocytes with intracellular 
calcium oscillations were reduced; 2. in patients with SpA structural alterations of the 
CaRS might determine the observed pattern and these alterations might be due to 
genetic variants. However another hypothesis should also be taken into account, i.e. the 
expression of calcium sensing receptors might vary in inflammatory diseases of the 
joints as demonstrated by Séjourné et al. who found reduced CaSR in monocytes 
isolated from synovial fluid and peripheral blood from patients with reumathoid arthritis 
[174]. We support this latter hypothesis. In fact in our experiments serum from PsA 
patients were demonstrated to cause a reduction of intracellular calcium oscillations in 
peripheral blood mononuclear cells of healthy blood donors. This suggests that in serum 
of patients soluble factors might act on monocytes and confer them new phenotypes. 
Although these soluble factors remain unknown, the role of cytokines may be 
hypothesized, but small metabolites may also be involved. We observed an inverse 
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significant correlation between the percentage of monocytes with intracellular calcium 
oscillations and uric acid. This finding poses the attention on a relevant metabolite well 
known to be implicated in another joint disease, gout. However in plasma of patients 
with gout, uric acid is usually above the upper reference limit, while in our series of 
SpA patients it was not. Therefore its potential pathogeneic role in these diseases is 
probably different from that described in gout, i.e. crystals deposits in joints, and a 
complex interplay between small uric acid variations and expansion of mMDSC appears 
a possible hypothesis.  
The interpretation of our findings might be limited by the fact that SpA patients were 
under treatment at enrollment. Therefore one might argue that the observed variations 
might be due to therapy not to disease. The study of a population of patients free of any 
medication is extremely difficult for the reasons already described above, i.e. diagnosis 
if often delayed but from symptom onset to diagnosis patients received usually 
symptom-guided therapy. At enrollment our patients, however, were on different 
therapies, the main being DMARDs and anti-TNF-α and a subset of 8 patients were 
enrolled before starting anti-TNF-α therapy and for them a second evaluation 6 months 
later was available. The percentage of monocytes with intracellular calcium oscillations 
was not correlated with the type of therapy or of drug used, and it did not vary before 
and after six months of anti-TNF-α therapy. Similarly therapy was not found to affect 
the expression levels of the studied cytokines, calprotectin and MMPs. Therefore our 
findings appear to be mainly disease- not drug- related. 
In conclusion the results of this study indicate that the analysis of the expression levels 
of inflammatory cytokines, calprotectin and MMPs in blood circulating mononuclear 
cells appear of no clinical utility in SpA diagnosis nor in the stratification of disease 
groups. SpA patients shown a reduced number of monocytes with intracellular calcium 
oscillations probably due to shift toward mMDSC phenotype which could involved in 
SpA inflammatory process.  
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